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In Brief
With buildup in the inflamed tissue,
lactate can exacerbate the inflammatory
response. Pucino et al. report that lactate
induces expression of its own
transporter, SLC5A12, driving lactate
uptake into CD4+ T cells and resulting in
increased IL17 production via PKM2/
STAT3 signaling and enhanced fatty acid
synthesis. They provide evidence that
targeting SLC5A12 may ameliorate
chronic inflammatory disorders.nc.
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Accumulation of lactate in the tissue microenviron-
ment is a feature of both inflammatory disease and
cancer. Here, we assess the response of immune
cells to lactate in the context of chronic inflammation.
We report that lactate accumulation in the inflamed
tissue contributes to the upregulation of the lactate
transporter SLC5A12 by human CD4+ T cells.
SLC5A12-mediated lactate uptake into CD4+ T cells
induces a reshaping of their effector phenotype,
resulting in increased IL17 production via nuclear
PKM2/STAT3 and enhanced fatty acid synthesis. It
also leads to CD4+ T cell retention in the inflamed tis-
sue as a consequence of reduced glycolysis and
enhanced fatty acid synthesis. Furthermore, anti-
body-mediated blockade of SLC5A12 ameliorates
the disease severity in a murine model of arthritis.
Finally, we propose that lactate/SLC5A12-induced
metabolic reprogramming is a distinctive feature of
lymphoid synovitis in rheumatoid arthritis patientsContext and Significance
Lactate is one of the most enriched by-products of cellular m
exacerbation of the inflammatory response in chronic inflamm
mingham, UK, and their collaborators have used human cells
drives inflammation. Here, they report on a mechanism that inv
into the cell. This transporter is expressed by a specific subs
flamed tissues. They discover that SLC5A12-driven lactate u
bolism, which supports a pro-inflammatory response by CD4+
clonal antibody shows promising results in a pre-clinical mod
CD4+ T cells.
Cell Metabolism 30, 1055–1074, Decem
This is an open access article under the CC BY-Nand a potential therapeutic target in chronic inflam-
matory disorders.
INTRODUCTION
The recent discovery of the fundamental role of metabolism in
immune cell biology is contributing immensely to our under-
standing of immune cell regulation (Buck et al., 2016; O’Neill
et al., 2016).
So far, most studies have focused on the role of metabolic
pathways in the establishment of the immune response. More
recently, novel signaling functions of metabolic intermediates
in the regulation of immunity, including the small metabolites
lactate, acetyl-CoA, succinate, itaconate, and others have
been revealed. The roles of metabolite signaling stretch from
regulation of cytokine production via effects on the cellular
redox state, to interactions with transcription factors binding
to specific cytokine promoter elements, to modulating the
activity of transmembrane ion channels, and interference with
cell migration and differentiation. Hence, the signaling functions
of metabolites extend beyond self-regulatory roles and includeetabolism in inflamed tissues. Its accumulation leads to the
atory disorders like rheumatoid arthritis. Researchers in Bir-
and tissues to investigate the processes by which lactate
olves a transporter known as SLC5A12, which brings lactate
et of lymphocytes, the CD4+ T cells, often infiltrating the in-
ptake leads to a stepwise reprogramming of cellular meta-
T cells. Targeting SLC5A12 pharmacologically with a mono-
el of rheumatoid arthritis characterized by the infiltration of
ber 3, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1055
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. SLC5A12 Expression by CD4+ T Cells Is Regulated by Activating and Inflammatory Stimuli
(A–C) Representative flow cytometry plots of SLC5A12 expression by CD4+ or CD8+ T cells from non-activated (n = 3; A) or anti-CD3 mAb-activated (n = 6; B) HC
PBMCs. Quantification shown in (C).
(D–F) Representative flow cytometry histograms (D and E) and quantification (F) of SLC5A12 expression by CD4+ T cells from non-activated HC (n = 4) and RA (n =
4; D and F), or anti-CD3mAb-activated HC (n = 4) and RA (n = 5; E and F) PBMCs. CD4+ T cells from non-activated RA SFMCs (n = 8; E and F) were also analyzed.
Briefly, PBMCswere cultured in RPMImedium supplementedwith 5%RAor HC autologous blood serum (BS), or 5%RA synovial fluid (SF); SFMCswere cultured
in RPMI medium supplemented with 5% autologous SF.
(G) Representative flow cytometry histograms (left) and quantification (right) of SLC5A12 expression by CD4+ T cells from non-activated or anti-CD3 mAb-
activated RA SFMCs. Briefly, cells were cultured in RPMI medium supplemented with 5% FBS (n = 3), 5% autologous BS (n = 8) or 5% autologous RA SF (n = 8).
Activated RA PBMCs cultured in 5% BS RPMI (n = 5) were used as controls (H). MFI, mean fluorescent intensity.
(legend continued on next page)
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cell-to-cell communication and sensing of micro-environmental
conditions, i.e., within the inflammatory microenvironment, to
elicit stress responses and cellular adaptation (Haas et al.,
2015, 2016; Tannahill et al., 2013).
Although known for its role in the muscle-liver Cori cycle and
neuron-astrocyte shuttle, lactate has mainly been seen as a
by-product of metabolism or as a biomarker in critical care at
best rather than a bioactive molecule, and its functional
effects have thus been neglected for long time. Far from being
inert, lactate accumulation in the disease microenvironment
has major effects on tissue-resident and infiltrating immune
cells. Recently reported outcomes include tumor escape
from immune surveillance mechanisms via reshaping of macro-
phage and effector T cell functions to immune-suppressive
and tumor promoting regulatory T cells and tumor-associated
macrophages (Angelin et al., 2017; Brand et al., 2016; Colegio
et al., 2014; Reina-Campos et al., 2017). In contrast, accumula-
tion of lactate in the tissue microenvironment in the course of
inflammatory disorders serves as an amplifier of inflammation
(Haas et al., 2015, 2016; Weyand et al., 2017). Lactate has
recently been shown to be a major source of carbons for the
tricarboxylic acid cycle (TCA), surprisingly even in excess of
glucose, both in normal and cancerous tissues (Faubert et al.,
2017; Hui et al., 2017). However, whether this contributes to its
signaling properties is not well understood.
The physiological lactate concentration in blood and
healthy tissues is approximately 1.5–3 mM, but it can rise to
10–40 mM at inflamed tissues as shown in tumor microenviron-
ments and arthritic joints as well as atherosclerotic plaques
and adipose tissue in obese individuals. Elevated levels of
lactate have also been reported in the serum of multiple scle-
rosis and Sjo¨gren’s syndrome patients, in the latter correlating
with fatigue and exercise intolerance (Pucino et al., 2017;
Amorini et al., 2014). Lactate is mainly produced in the cyto-
plasm during hypoxia or as a consequence of aerobic glycol-
ysis in proliferating cells, and it is then secreted through the
plasma membrane. This transport is dependent on solute car-
rier transporters that perform proton-lactate symport (i.e.,
MCT1-4) or sodium-dependent transport (i.e., SLC5A8 and
SLC5A12). Indeed, only MCT1 (also known as SLC16A1, Km
4.5) and MCT4 (also known as SLC16A3, Km 28) have a high
specificity for lactate and broad tissue expression. Sodium-
coupled lactate transport is carried out by the high-affinity
transporter SLC5A8 or the low-affinity transporter SLC5A12,
which have been initially reported for their expression in kidney
(Srinivas et al., 2005; Gopal et al., 2007). More recently, we
have reported the expression of SLC5A12 by CD4+ T cells
(Haas et al., 2015). Even though some transporters facilitate
extrusion (e.g., MCT4) and others influx (e.g., MCT1) of lactate,
the main factor determining the transport direction is the lactate
gradient, facilitating lactate import when extracellular lactate(H) Representative flow cytometry histograms (left) and quantification (right) of SL
mAb or control rat sera.
(I and J) SLC5A12 mRNA (n = 5; I) and protein (representative western blots [left
isolated from HC PBMCs, then activated with anti-CD3 and anti-CD28 mAb in th
Lactate-untreated CD4+ T cells (CN, dotted line) set to 1.
One-way ANOVA (C and F) or two-tailed Student’s t test (G–J). Data expressed a
and S3.is high, such as in inflamed tissues (Halestrap and Wilson,
2012; Srinivas et al., 2005).
Formore than 50 years, the inflamed joint has been recognized
as a site of low glucose and high lactate concentrations (Goetzl
et al., 1971; Treuhaft and MCCarty, 1971), reflective of the
intense cellular turnover in the rheumatoid pannus. Synovial fi-
broblasts adopt an anaerobic glycolysis type of metabolism,
producing and secreting high amounts of lactate in the microen-
vironment. There, lactate contributes to the regulation of the
functions of surrounding cells (i.e., plasticity), including infil-
trating immune cells (Fujii et al., 2015).
Rheumatoid arthritis (RA) is characterized by three distinc-
tive histological pattern of synovitis (i.e., pathotypes). In 40%
of patients, the inflammatory infiltrate is constituted mainly
by monocyte and/or macrophages in the synovial sublining,
i.e., myeloid pathotype. A rarer subset, 20% of RA patients,
is characterized by a prevalent fibroid signature, i.e., fibroid
and pauci-immune pathotype. In the remaining 40% of RA pa-
tients, immune cells can be found spatially grouped in follic-
ular structures, which can acquire features of secondary
lymphoid organs (SLO) with high T and B cell infiltration and
segregation, i.e., lymphoid pathotype. These structures, which
develop in the inflammatory tissue, are called ectopic
lymphoid-like structures (ELS). The recognition that ELS may
play a key pathogenic role in autoimmunity and may be ex-
ploited as potential biomarker for disease evolution and
response to therapy is gaining attention (Pitzalis et al., 2013,
2014; Bombardieri et al., 2017). Our group has recently found
that SLC5A12 is highly expressed in human RA synovial tis-
sues. Strikingly, its levels significantly increased in correlation
with the RA synovial tissue T cell score and with the formation
of ELS which are rich in IL17 (Haas et al., 2015; Peters et al.,
2011; Jones et al., 2015; Jones and Jones, 2016), thus sug-
gesting a possible role of lactate/SLC5A12-induced metabolic
signaling in promoting chronic inflammation in RA.
Here, we explored the response of CD4+ T cells to lactate
in the context of the tissue microenvironment in inflammatory
disorders. We identified several mechanistic steps leading
from the influx of lactate into CD4+ T cells to the plastic reshaping
of their effector functions and their induced exacerbation of the
inflammatory response.
RESULTS
The Expression of the Lactate Transporter SLC5A12 by
Immune Cells Is Regulated by Activating and
Inflammatory Stimuli
Lactate modulates CD4+ T cell migratory abilities and cytokine
production via the sodium-coupled lactate transporter
SLC5A12, which is selectively expressed by CD4+ but not by
CD8+ T cells, at least in the murine system (Haas et al., 2015).C5A12 expression by CD4+ T cells from RA SFMCs (n = 5) incubated with 3C7
] and densitometric quantification [right; n = 3]; J) expression by CD4+ T cells
e presence of sodium lactate (10 mM) and/or SLC5A12 Ab, or left untreated.
s mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001. See also Figures S1, S2,
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To assess whether the expression of SLC5A12may be regulated
by activating stimuli, peripheral blood mononuclear cells
(PBMCs) from healthy control (HC) subjects were activated
for 48 h with anti-CD3 monoclonal antibody (mAb) or left un-
treated. Activation led to upregulation of SLC5A12 by peripheral
CD4+ while CD8+ T cells were mostly negative (Figures 1A–1C).
In the same experiment, activation led to upregulation of
SLC5A12 also by peripheral CD14+ monocytes and to a less
extent by CD19+ B cells (Figures S1A–S1C), conceivably via
signals initiated by T cell interactions with antigen presenting
cells upon CD3 stimulation in the context of the PBMCs. In
comparison, the same immune cell subsets were negative
for SLC5A12 or expressed it at low levels in untreated PBMCs
(Figures 1A–1C and S1A–S1C). In additional experiments
we carried out, we observed that SLC5A12 was already upre-
gulated by CD4+ T cells at the 12-h activation time point of
HC PBMCs and that indeed this time point may have the peak
of SLC5A12 expression on the cell membrane. Indeed,
SLC5A12 expression on the membrane was reduced at the
subsequent 24- and 48-h time points (Figure S1D).
Next, we activated PBMCs from HC or RA subjects for 48 h
with anti-CD3 mAb or left them untreated and then compared
the expression of SLC5A12 by CD4+ T cells. We found that
peripheral RA CD4+ T cells became SLC5A12+ only upon T cell
receptor (TCR) engagement, much like their HC counterparts
(Figures 1D–1F). We analyzed the phenotype of CD4+SLC5A12+
T cells in further depth in Figure 3.
To test whether inflammatory cues, in addition to activating
stimuli, may also contribute to the expression of SLC5A12
by CD4+ T cells, we cultured HC or RA PBMCs in medium
supplemented with 5% HC or RA autologous blood serum
(BS), respectively, or with 5% RA synovial fluid (SF). The
percentage of CD4+SLC5A12+ T cells was very low in both
non-activated HC and RA PBMCs cultured in medium contain-
ing autologous BS or RA SF (Figures 1D and 1F). Anti-CD3
mAb-mediated activation led to upregulation of SLC5A12 by
CD4+ T cells; however, no difference was observed in the
percentage of CD4+SLC5A12+ T cells from HC and RA PBMCs
activated in medium containing autologous BS (Figures 1E
and 1F). In contrast, anti-CD3 mAb-mediated activation of
RA but not of HC PBMCs in the presence of 5% RA SF led
to a robust further upregulation of SLC5A12 by CD4+ T cells
as compared to HC and RA CD4+ T cells from PBMCs acti-
vated in the presence of BS (Figures 1E and 1F). Importantly,
we observed that SLC5A12 expression levels by CD4+ T cells
from RA PBMCs activated in the presence of RA SF were com-
parable to those expressed by CD4+ T cells in synovial fluid
mononuclear cells (SFMCs) from RA joints in the absence of
any ex vivo stimulation (Figures 1E and 1F). We also found
that CD4+ T cells from RA SFMCs presented high levels of
SLC5A12 irrespective of any activating or inflammatory stimuli
we used ex vivo, as compared to CD4+ T cells from RA PBMCs
activated in the presence of autologous BS, suggesting they
have already experienced maximal levels of SLC5A12 inducing
factors, i.e., antigen and exposure to inflammatory cues (Fig-
ure 1G). As for RA SFMCs, when we analyzed mononuclear
cells (MCs) from inflamed tonsils excised from patients sub-
jected to tonsillectomy, CD4+ T cells were SLC5A12+, indepen-
dent of any activating stimuli we used ex vivo (Figures S2A–S2C1058 Cell Metabolism 30, 1055–1074, December 3, 2019and S2G). Likewise, analysis of CD14+ and CD19+ cells by
fluorescence-activated cell sorting (FACS) or CD68+ and
CD20+ cells by fluorescence microscopy in the same samples
revealed that they were SLC5A12+, independent of any acti-
vating stimuli we used ex vivo (Figures S2D–S2G). In contrast,
CD8+ T cells were mostly negative for SLC5A12 (Figures
S2A–S2C and S2G), which was consistent with data in Figures
1A–1C.
We then wondered whether lactate may contribute to the
regulation of the expression of SLC5A12. We generated mAbs
targeting SLC5A12 by immunization of rats with a peptide
comprising the predicted main extracellular loop of SLC5A12
(Gopal et al., 2007), with the aim of inhibiting the carrier function
of the transporter. Out of 400-screened clones, we selected
3C7 for its ability to specifically recognize SLC5A12 (Figure S3).
Treatment of RA SFMCs with 3C7 mAb led to reduced expres-
sion of the transporter itself by CD4+ T cells (Figure 1H). Further-
more, incubation of anti-CD3 and anti-CD28 mAb-activated
peripheral CD4+ T cells—isolated from HC PBMCs with mag-
netic bead-based negative selection prior to activation—with
10 mM sodium lactate, a concentration similar to what is
measured in RA SF (Haas et al., 2015), contributed to the induc-
tion of SLC5A12 expression both at mRNA and protein level.
Pre-incubation with a blocking anti-SLC5A12 polyclonal anti-
body (SLC5A12 Ab; Haas et al., 2015) prevented lactate-induced
upregulation of SLC5A12 (Figures 1I and 1J). These data sug-
gested that accumulation of extracellular lactate, such as at
sites of inflammation, contributes to the upregulation of the
lactate transporter SLC5A12 by activated CD4+ T cells.
SLC5A12 Facilitates Lactate Uptake and Oxidation by
TCA Cycle in Activated CD4+ T Cells
Having observed an increase in the expression levels of the
lactate transporter SLC5A12 in response to activating and in-
flammatory stimuli in CD4+ T cells (Figure 1) and knowing that
these cells are mostly MCT1 (Haas et al., 2015), we wondered
whether SLC5A12 may serve as the main carrier of lactate into
activated CD4+ T cells that have reached the inflamed tissue
and hence are exposed to a high concentration of extracellular
lactate.
Indeed, exposure to lactate caused a decrease in glucose
uptake by activated CD4+ T cells, which was reversed by incuba-
tion of cells with SLC5A12 Ab (Figure 2A). No significant change
in glutamine uptake was observed in the same experiment
indicating a specific block in glycolysis (Figure 2A). NAD+ is a
key co-factor of the sixth reaction of the glycolytic cascade
catalyzed by glyceraldehyde 3-phosphate dehydrogenase. As
a consequence of this reaction, NAD+ is reduced to NADH,
which acts as an inhibitory feedback on glycolysis. NADH can
be re-oxidized to NAD+ via the lactate dehydrogenase reaction
converting pyruvate to lactate. This reaction is important to
maintain a steady flux of glycolysis. However, lactate dehy-
drogenase can perform the reverse reaction when cells are
exposed to high levels of extracellular lactate as it happens at
the site of inflammation, with reduction of NAD+ to NADH and
consequent inhibitory feedback on glycolysis. Indeed, upon
exposure to lactate we observed a drop in the NAD+/NADH
ratio in activated CD4+ T cells, indicating a relative increase in
intracellular NADH (Figure 2B). Data in Figures 2A and 2B were
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Figure 2. Lactate Uptake by CD4+ T Cells Impacts Intracellular Utilization of Central Carbon Metabolic Pathways
(A) Glucose and glutamine uptake rates for CD4+ T cells isolated from HC PBMCs, then activated with anti-CD3 and anti-CD28 mAbs for 24 h followed by further
48-h culture with lactate alone or in the presence of SLC5A12 Ab, or left untreated, in medium containing low glucose (5 mM) and 5% FBS (n = 3, each in
duplicate).
(B) NAD+ and NADH intracellular levels in CD4+ T cells (n = 2) treated with sodium lactate (10 mM) for the indicated time points after 72-h activation and shown as
NAD+/NADH ratio. Lactate-untreated CD4+ T cells (CN, dotted line) set to 1.
(C) Seahorsemeasurements of extracellular acidification (left) and oxygen consumption (right) rates (ECAR andOCR, respectively) by 12-h-activated CD4+ T cells
(n = 3, technical replicates). 1 h prior to the experiment, cells were seeded in a 96-well microplate in XF Assay medium in the presence of 10 mM of glucose.
Sodium lactate (10 mM) or PBS was injected during measurement. Data representative of n = 2 independent experiments.
(D and E) 13C tracing of [U13C]-lactate into pyruvate and citrate. Activated CD4+ T cells were incubated for 48 h with [U13C]-lactate in the presence or absence of
SLC5A12 Ab in medium containing low glucose (5 mM) and 5% FBS (n = 2, each in duplicate). Polar metabolites were extracted, analyzed by LC-MS and peak
areas of mass isotopologues normalized to cell number are represented.
(F and G) Acetyl-CoA (F) and citrate (G) intracellular levels in CD4+ T cells (n = 3) treated with sodium lactate (10 mM) for the indicated time points after 72-h
activation. Lactate-untreated CD4+ T cells (CN, dotted line) set to 1.
Two tailed Student’s t test. Data expressed as mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001.
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Figure 3. Lactate Shapes the Effector Phenotype of CD4+ T Cells at the Site of Inflammation via SLC5A12
(A) RelativemRNA expression levels of IL17A, IL22, IFNg, IL6, IL10, and TGFb as assessed by qRT-PCR in tonsil CD4+ T cells treated with sodium lactate (10mM)
and/or SLC5A12 Ab or left untreated (n = 5). Levels of mRNA of each cytokine expressed by lactate-untreated CD4+ T cells were set to 1 (CN, dotted line).
(B) IL-17A and IFNg ELISAs from supernatants of tonsil CD4+ T cells treated as in (A), (n = 5, each in duplicate).
(C) Relative mRNA expression levels of RORgT, FOXO1, FOXP3, PD1,CXCR5, and BCL6 as assessed by qRT-PCR in tonsil CD4+ T cells treated as in (A), (n = 5).
Levels of mRNA of each cytokine expressed by lactate-untreated CD4+ T cells set to 1 (CN, dotted line).
(D) Representative flow cytometry plots of CD4+IL17+, CD4+FOXP3+, CD4+PD1+CXCR5+, CD4+IFNg+, and CD4+IL10+ tonsil CD4+ T cells incubated in the
presence or absence of SLC5A12 Ab (left; n = 3). Quantification bar charts (right).
(E) Percentage of IFNg+, IL17A+, IL21+, Treg (CD25+Foxp3+), and cytokine-negative (Neg CKS; left) or RORgt+, Treg (CD25+Foxp3+), Tfh (CXCR5+PD-1+ICOS+),
and Tbet+ (right) CD4+SLC5A12+ T cell subsets in 48-h activated human HC PBMCs (n = 5).
Two-tailed Student’s t test. Data expressed as mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001.consistent with the reduced rate of glycolysis (ECAR) we
observed in the presence of lactate (Figure 2C, left), while the ox-
ygen consumption rate (OCR) in the mitochondria was not
affected by lactate (Figure 2C, right).
We reasoned that these findings might be explained by an
uptake of lactate by activated CD4+ T cells when they are in an
inflamed, lactate-rich tissue. Pyruvate may then enter the TCA
cycle, but since we did not observe an increase in mitochondrial1060 Cell Metabolism 30, 1055–1074, December 3, 2019OCR, we wondered what the fates of the lactate-derived
carbons were. To test our rationale in a direct fashion, we per-
formed mass spectrometry-based tracer analysis of [U13C]-
lactate. Specifically, we activated CD4+ T cells and then incu-
bated them with [U13C]-lactate in the presence or absence of
SLC5A12 Ab, similarly to Figure 2A. We then extracted intracel-
lular metabolites and performed mass spectrometry analysis.
We found that a significant proportion of 13C-carbons from
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Figure 4. Lactate Induces IL17 via Nuclear PKM2- and FAS-Mediated STAT3 Phosphorylation
CD4+ T cells were isolated from HC PBMCs and activated with anti-CD3 and anti-CD28 mAb.
(A) ROS levels in CD4+ T cells (n = 3) treated with sodium lactate (10 mM) for the indicated time points after 72-h activation. PBS and H2O2 were used as negative
and positive control, respectively.
(B) Representative western blots showing nuclear PKM1/2, P-STAT3, STAT3, and cytosolic PKM1/2 in activated CD4+ T cells treated with sodium lactate (10mM)
for the indicated time points or left untreated (CN). Histone H3 and b-actin were used as controls for nuclear and cytosolic fraction, respectively. Data repre-
sentative of n = 3 independent experiments.
(C) Representative western blots (left) and densitometric quantification (right; n = 3) of P-STAT3, STAT3, P-STAT1, and STAT1 expression by activated CD4+
T cells treated with sodium lactate (10 mM) and/or SLC5A12 Ab, or left untreated. Untreated CD4+ T cells (CN, dotted line) set to 1.
(legend continued on next page)
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[U13C]-lactate were incorporated in to pyruvate (M+3) and citrate
(M+2), and that this effect was reduced by incubation with
SLC5A12 Ab (Figures 2D and 2E). Additionally, theM0 (unlabeled
isotope) in each of these metabolites is also reduced: as the
antibody blocks the lactate transporter SLC5A12, influx of 13C-
lactate but also of glucose-derived 12C-lactate is reduced as a
consequence of SLC5A12 ‘‘re-importing’’ some lactate previ-
ously secreted by the cell. Consistent with these data, we found
an increase in citrate and acetyl-CoA levels in activated CD4+
T cells exposed to lactate at different time points (Figures 2F
and 2G).
Altogether, these data suggested that when exposed to high
levels of lactate, such as those found in an inflamed tissue, acti-
vated CD4+ T cells could take up lactate via the specific carrier
SLC5A12. This causes glycolysis to slow down (through NAD)
and in turn leads to more carbons going into the TCA cycle.
Therefore, we hypothesized that the carbon flux we observed
may be required to replenish intermediates of the TCA cycle
that feed biosynthetic processes.
Lactate Shapes the Effector Phenotype of CD4+ T Cells
at the Site of Inflammation via SLC5A12
We then tested the effects of exposure to inflamed tissue levels
of lactate in the presence or absence of SLC5A12 Ab on the
effector phenotype of anti-CD3 and anti-CD28 mAb-activated
CD4+ T cells that were isolated from inflamed tonsils.
We observed an upregulation of IL17A and IFNg mRNAs in
response to lactate, which was reversed by incubation with
SLC5A12 Ab. IL17-family member IL22 also showed a tendency
to upregulation in response to lactate. We did not observe any
significant modulation in other cytokines (i.e., inflammatory IL6
or immunosuppressive IL10 and TGFb; Figure 3A). However,
the observed upregulations at the mRNA level resulted in only
IL17A but not IFNg upregulation at the protein level upon treat-
ment with lactate and again this response was abolished by in-
cubation with SLC5A12 Ab (Figure 3B).
Supporting the findings of IL17 upregulation, also the mRNA
of RORgT, the signature transcription factor of the Th17 T cell
subset, was elevated as a consequence of exposure to lactate
and again this response was abolished by incubation with(D) Representative western blots (left) and densitometric quantification (right; n =
treated with sodium lactate (10 mM) for the indicated time points or left untreate
(E) Representative western blots showing cytosolic and mitochondrial P-ACC an
indicated time points or left untreated (CN). b-actin and VDAC were used as contro
n = 2 independent experiments.
(F) Mass spectrometry carbon tracer analysis of palmitate in 48-h [U13C]-lactate-fe
h; n = 2, time points 72 and 96 h).
(G) Representative western blots (left) and densitometric quantification (right; n =
sodium lactate (10mM) alone or in combination with C75 (10 mM), TOFA (20 mM), a
set to 1.
(H) IL-17A and IFNg ELISAs from supernatants of activated CD4+ T cells treated
(20 mM), DHEA (20 mM), DASA (20 mM), AICAR (1mM), or left untreated (n = 5, each
duplicate).
(I) Representative western blots (left) and densitometric quantifications (right; n =
from Slc5a12 WT or KO mice, treated with sodium lactate (10 mM) or left untreat
Slc5a12 WT or KO mice, treated with sodium lactate (10 mM) or left untreated (n
Two-tailed Student’s t test (A), (C), (F), (H), and (I) or one-way ANOVA (G). Data ex
versus lactate (H).
(J) Schematic depicting the described findings: lactate modulates IL17 expressi
induction, converging on STAT3-induced transcription of IL17. See also Figure S
1062 Cell Metabolism 30, 1055–1074, December 3, 2019SLC5A12 Ab (Figure 3C). Interestingly, the expression of the
transcription factor FOXO1, which limits the differentiation of
CD4+ T cells into the Th17 subset and the consequent produc-
tion of IL17 (Ouyang et al., 2009), was reduced by treatment
with lactate, even though incubation with SLC5A12 Ab did not
have any effects on its expression (Figure 3C). Consistent
with data in Figure 3A, expression of FOXP3, the signature tran-
scription factor of regulatory T (Treg) cells producing TGFb and
IL10 was not impacted by lactate treatment (Figure 3C). Further-
more, we observed a lactate-dependent regulation of PD1 but
not of the transcription factor BCL6 or the chemokine receptor
CXCR5 (Figure 3C).
To gain direct insights on the impact of lactate on the effector
phenotype of CD4+ T cells at the site of inflammation, we con-
ducted intracellular staining of CD4+IL17+ (Th17), CD4+IFNg+
(Th1), CD4+PD1+CXCR5+ (Tfh), and CD4+FOXP3+ or
CD4+IL10+ (Treg) subsets from activatedMCs from inflamed ton-
sils (Figure 3D). Incubation with SLC5A12 Ab resulted in a reduc-
tion in the Th17 and Tfh T cell subsets with a less pronounced
reduction in the Th1 and no modulation of the Treg subsets
(Figure 3D). We further characterized the phenotype of human
CD4+SLC5A12+ T cells from 48-h activated HC PBMCs and
observed that RORgt+, CXCR5+PD-1+ICOS+ (Tfh), and Tbet+
are the CD4+ T cell subsets that are most positive for SLC5A12
while CD25+Foxp3+ (Treg) CD4+ T cells are less frequently pos-
itive for SLC5A12 (Figure 3E, right). Furthermore, we observed
that IFNg+ (signature cytokine of Tbet+), IL17A+ (signature cyto-
kine of RORgt+), and IL21+ (signature cytokine of Tfh) CD4+
T cells are mostly positive for SLC5A12, while Treg and CD4+
T cells that do not produce cytokines (Neg CKS) are much less
frequently positive for SLC5A12 (Figure 3E, left).
Lactate Induces IL17 Expression via Nuclear PKM2- and
Fatty Acid Synthesis-Mediated STAT3 Phosphorylation
We next asked how lactate may promote IL17 expression
and whether the lactate uptake via SLC5A12 and its induced
increase of citrate may play a role in this response of CD4+
T cells. Exposure of activated CD4+ T cells to inflamed
tissue levels of lactate caused a rapid, marked elevation of
intracellular reactive oxygen species (ROS; Figure 4A). The3) of P-ACC, ACC, P-AMPK, and AMPK expression by activated CD4+ T cells
d (CN). Untreated CD4+ T cells (CN, dotted line) set to 1.
d ACC in activated CD4+ T cells treated with sodium lactate (10 mM) for the
ls for cytosolic andmitochondrial fraction, respectively. Data representative of
d activated CD4+ T cells treated as in Figure 2D (n = 4, time points 0, 24, and 48
2) of P-STAT3 and STAT3 expression by activated CD4+ T cells treated with
nd DHEA (20 mM) or left untreated (CN). Untreated CD4+ T cells (CN, dotted line)
with sodium lactate (10 mM) alone or in combination with C75 (10 mM), TOFA
in duplicate; for lactate + DASA +C75 or lactate + DASA + TOFA, n = 2, each in
3) of P-ACC, ACC, P-STAT3, and STAT3 expression by activated CD4+ T cells
ed (CN). Also, IL-17A ELISA from supernatants of activated CD4+ T cells from
= 3, each in duplicate).
pressed as mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001; ###p% 0.001
on by activating two pathways, PKM2 translocation into the nucleus and FAS
4.
glycolytic enzyme pyruvate kinase M2 (PKM2) functions as a
homo-tetramer in the cytosol converting phosphoenolpyruvate
to pyruvate in the last reaction of glycolysis. ROS can promote
the oxidation and subsequent dimerization of PKM2. Dimers
of PKM2 localize in the nucleus where they phosphorylate
transcription factors, including signal transducer and activator
of transcription 3 (STAT3), a known transcriptional regulator of
IL17 (Shirai et al., 2016; Yang et al., 2007). Indeed, we found
that lactate promoted the translocation of PKM2 in the nucleus
and the phosphorylation of STAT3 (Figure 4B). Activation of
STAT3 occurred as early as 1 h after cell treatment with
lactate (Figure 4B) and could still be observed at 12 h (Figure 4C).
STAT1, another STAT family member implicated in Th17
differentiation (Peters et al., 2015), was also phosphorylated
at the same time point (Figure 4C). Phosphorylation of STAT1/3
returned to basal levels upon incubation with SLC5A12 Ab
(Figure 4C).
De novo fatty acid synthesis (FAS) is another biological pro-
cess that has been implicated in the differentiation of the Th17
T cell subset (Berod et al., 2014). We observed that activated
CD4+ T cells take up lactate and consequently increase the
intracellular pool of citrate and acetyl-CoA (Figures 2D–2G),
which are the substrates of FAS. We therefore asked whether
exposure to lactate may induce FAS in these cells, by assess-
ing the activation levels of acetyl-CoA-Carboxylase (ACC) and
50-AMP activated protein kinase (AMPK), two key enzymes in
the regulation of fatty acid metabolism. We found that exposure
to lactate caused a decrease in phosphorylated ACC at Serine
79 indicating increased ACC enzymatic activity (Figure 4D).
Consistently, we also detected a decrease in phosphorylated
AMPKa at Threonine 172 (Figure 4D), indicating reduced
AMPK enzymatic activity. ACC exists in humans and other
mammals as two isoforms, ACC1 and ACC2. Whereas ACC1
is present in the cytosol and initiates de novo synthesis of fatty
acids by converting acetyl-CoA to malonyl-CoA (Chirala and
Wakil, 2004), ACC2 is associated with the outer mitochondrial
membrane and is a key enzyme in the oxidation of fatty acids
(FAO; Abu-Elheiga et al., 2000, 2001). We found a marked
decrease in phosphorylated ACC in the cytosol of activated,
lactate-treated CD4+ T cells but no major change in phosphor-
ylated ACC in the mitochondria (Figure 4E).
To test any effects of lactate on FAO in a more direct fashion,
we measured OCR in activated CD4+ T cells cultured in 2.5 mM
glucose and 1 mM BSA-palmitate that served as a substrate for
FAO, or BSA alone. BSA-palmitate raised OCR as compared
to BSA alone, but lactate did not affect either conditions. Addi-
tion of etomoxir, an inhibitor of the key enzyme carnitine palmi-
toyltransferase-1 (CPT-1) in the initiation of FAO, reduced
BSA-palmitate OCR to the levels observed in the BSA alone
control and again this effect was not affected by lactate
(Figure S4A).
To test whether lactate feeds FAS, we incubated activated
CD4+ T cells with [U13C]-lactate and traced 13C labeling in palmi-
tate. Lactate 13Cs labeled nearly 50% of newly synthesized
palmitate. This effect was inhibited in cells that were incubated
with SLC5A12 Ab, indicating incorporation of lactate-derived
carbons in palmitate backbone (Figure 4F). An induction of
FAS by lactate was also confirmed by an increment in total
free fatty acid (FFA) cellular content (Figure S4B).Given the importance of both STAT3 and FAS in the differen-
tiation of the Th17 T cell subset (Shirai et al., 2016; Yang et al.,
2007; Berod et al., 2014; Shi et al., 2011), we asked whether
lactate may modulate the expression of IL17 via either or both
pathways. We treated activated CD4+ T cells with 5-(tetradecy-
loxy)-2-furoic acid (TOFA), a competitive inhibitor of ACC (Berod
et al., 2014), 4-methylene-2-octyl-5-oxotetrahydrofuran-3-car-
boxylic acid (C75), a FAS inhibitor (Shen et al., 2017) and dehy-
droepiandrosterone (DHEA), an inhibitor of glucose-6-phos-
phate dehydrogenase (G6PDH, Raineri and Levy, 1970;
Gordon et al., 1995), a key step in the pentose phosphate
pathway (PPP) providing NADPH equivalents for FAS (see also
Figures 6C–6E). As expected, all three inhibitors increased
phosphorylated ACC levels (Figure S4C), indicating an inhibitory
effect on FAS. DHEA also increased phosphorylated AMPK
(Figure S4C), which is suggestive of a switch toward FAO. With
these three compounds, we then tested the impact of lactate-
induced FAS on STAT3 activation and IL17 production. All
three compounds reduced lactate-induced phosphorylation of
STAT3 (Figure 4G) and expression of IL17A (Figure 4H). Also,
the AMPK activator aminoimidazole-4-carboxamide 1-b-D-ribo-
furanoside (AICAR; Corton et al., 1995) and the potent and
selective PKM2 activator N,N’-diarylsulfonamide (DASA), which
stabilizes cytosolic PKM2 homo-tetramers and prevents PKM2
dimers translocation into the nucleus (Anastasiou et al., 2011),
markedly reduced the expression of IL17A (Figure 4H). Interest-
ingly, a co-treatment with DASA and C75 or TOFA resulted in an
additional reduction of lactate-induced IL17A expression as
compared to each compound alone (Figure 4H).
To further support our findings, we took advantage of a new
Crispr-Cas9 Slc5a12 KO mouse. We show that in response to
lactate both ACC and STAT3 phosphorylation as well as IL17
production are impaired (Figure 4I).
Taken together these data indicate that lactatemodulates IL17
expression by activating two pathways, PKM2 translocation into
the nucleus and enhanced FAS, converging on STAT3-induced
transcription of IL17 (Figure 4I).Reduced Glycolysis and Enhanced FAS Are the
Mechanisms throughWhich Lactate InducesCD4+ TCell
Retention in the Inflamed Tissue
Building upon our previous findings that inflamed tissue levels
of lactate induce a ‘‘stop migration signal’’ in activated CD4+
T cells (Haas et al., 2015; Pucino et al., 2017), we assessed the
impact of interfering with SLC5A12 function—via the use of
both SLC5A12 Ab and the mAbs we generated—on human
CD4+ T cell migration in vitro and ability to egress from the in-
flamed tissue ex vivo. We started by culturing equal size tissue
sections from juxtaposing areas of tonsil biopsies—isolated
from patients who had been subjected to tonsillectomy—in the
presence or absence of lactate and/or SLC5A12 Ab. We then
assessed by flow cytometry the type and number of immune
cells released in the culture media in each condition (Figure 5A).
Lactate reduced the egress of CD4+ T cells as compared to the
control condition and this effect was reversed by SLC5A12 Ab.
Lactate also reduced the egress of CD14+ cells but treatment
with SLC5A12 Ab did not reverse this effect, indicating
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Figure 5. SLC5A12 Blockade Promotes the Egress of CD4+ T Cell from the Inflamed Tissue
(A) Organ culture schematic describing the analysis performed to assess the egress of mononuclear cells (MCs) from the inflamed tissue.
(B) Analysis of MCs (CD4+, CD8+, CD19+, and CD14+) egress from tonsil tissues (n = 3, each in duplicate) cultured with sodium lactate (10 mM) and/or SLC5A12
Ab, or left untreated. Untreated MCs (CN, dotted line) set to 100.
(C and D) Representative flow cytometry plots (D) and quantification (E) of egressed CD4+ T cells from RA synovial tissues (n = 3) cultured with sodium lactate
(10 mM) and/or SLC5A12 Ab, 3C7 mAb, 10E11 mAb, or left untreated. Untreated MCs (CN, dotted line) set to 100.
Two-tailed Student’s t test. Data expressed as mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001. See also Figure S5.No significant effects were observed by treatments with lactate
and lactate plus SLC5A12 Ab in CD8+ or CD19+ cells (Figure 5B).
We then sought to assess whether a similar effect could be
observed in synovial tissue biopsies from patients who had
been subjected to joint replacement. Concurrently, we also as-
sessed whether the SLC5A12 mAbs we generated were able
to reverse lactate-induced block on CD4+ T cell migratory abili-
ties. We treated activated CD4+ T cells with lactate or left them
untreated in the presence or absence of SLC5A12 Ab or seven
SLC5A12 mAb clones. We then assessed cell chemokinesis
in response to the chemokine CXCL10 in trans-wells. As ex-
pected, SLC5A12 Ab reversed the ‘‘stop migration signal’’
induced by lactate (Figure S5A; Haas et al., 2015). In addition,
the mAb clones 3C7 and 9G7 were able to consistently reverse
the ‘‘stop migration signal’’ induced by lactate (Figure S5A).
Furthermore, as shown in Figure S3, 3C7 mAb was able to spe-
cifically recognize SLC5A12. We therefore tested 3C7 mAb
alongside SLC5A12 Ab in the ex vivo egress model in synovial
tissues. Again, SLC5A12 Ab was able to reverse the lactate-
mediated retention of CD4+ T cell in the tissue and a similar effect
was obtained with 3C7 mAb (Figures 5C and 5D).
Next, we asked how the metabolic adaptation of activated
CD4+ T cells to inflamed tissue levels of lactate impacted on their
response to migratory stimuli. Glycolysis is required for the
motility of activated, murine CD4+ T cells (Haas et al., 2015),1064 Cell Metabolism 30, 1055–1074, December 3, 2019and FAS supports invasiveness of inflamed tissues by peripheral
CD4+ T cells (Shen et al., 2017).
We first analyzed the effect of exposure of activated, human
CD4+ T cells to lactate on several glycolytic enzymes in a time-
course experiment. We observed reduced levels of hexokinase
1 (HK1), HK2, phosphofructokinase (PFK), enolase1a and
PKM1/2 (Figure 6A), indicating reduced rates of glycolysis,
consistent with data in Figures 2A–2C. However, lactate-
induced downregulation of HK1 and enolase1a but not of
HK2 and PKM1/2 was impeded by cell incubation with
SLC5A12 Ab (Figure 6B). These data suggest specific check-
points of lactate-mediated control of glycolysis, in addition to
the observed increased reduction of NAD+ to NADH, as shown
in Figure 2B. Based on our observation that lactate caused an
increase in the intracellular pools of citrate and acetyl-CoA,
we investigated whether lactate may induce post-translational
acetylation of cytosolic proteins in a 12-h time course but we
did not observe any major changes (Figure S6A). This potential
checkpoint control will require further investigations.
Intracellular localization of HK2 was suggested to serve as
a checkpoint channeling intracellular metabolic fluxes. While
cytosolic HK2 mediates glycolysis, VDAC-dependent binding
of HK2 to the outer membrane of mitochondria promotes
cell survival (Anderson et al., 2017; Woldetsadik et al., 2017;
Mathupala et al., 2009; Anflous-Pharayra et al., 2007). Indeed,
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Figure 6. Lactate Reduces the Motility of CD4+ T Cells via Reduced Glycolysis and Enhanced FAS
(A) Representative western blots (left) and densitometric quantification (right; n = 3) of HK1, HK2, PFK, enolase 1a, and PKM1/2 expression by activated CD4+
T cells treated with sodium lactate (10 mM), or left untreated. Untreated CD4+ T cells (CN, dotted line) set to 1.
(B) Representative western blots (left) and densitometric quantification (right; n = 3) of HK1, HK2, enolase 1a, PKM1/2, GCK, and aldolase expression by activated
CD4+ T cells treated with sodium lactate (10 mM) and/or SLC5A12 Ab, or left untreated. Untreated CD4+ T cells (CN, dotted line) set to 1.
(C) Representative western blots showing mitochondrial and cytosolic HK2 in activated CD4+ T cells treated with sodium lactate (10 mM) for the indicated time
points or left untreated (CN). VDAC and b-actin were used as controls for mitochondrial and cytosolic fraction, respectively. Data representative of n = 2 in-
dependent experiments.
(legend continued on next page)
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mitochondrial HK2 may favor glucose-6-phosphate entry in
the PPP producing NADPH equivalents and anabolic interme-
diates (Cheung et al., 2012). We found an increase in mitochon-
drial HK2 after 4-h lactate treatment as compared to cells left
untreated (Figure 6C). This observation was supported by
confocal microscopy data showing co-localization of HK2 with
mitochondria upon 4 h treatment with lactate (Figure 6D). We
also found a reduction in the NADP+/NADPH ratio at 1 h and
4 h after cell treatment with lactate (Figure 6E), consistent with
an increased shunt of glucose-6-phosphate into PPP and with
the observed induction of FAS. The observed inhibition of
PKM2 may also contribute to divert glucose into the PPP and
thereby generate NADPH (Le Goffe et al., 2002). Therefore, we
asked whether induction of FAS by lactate might play a role
in the entrapment of CD4+ T cells in the inflamed tissue. Acti-
vated CD4+ T cells were treated with lactate in the presence of
DHEA, TOFA, and C75 or left untreated and then subjected to
chemokinesis in response to either CCL20 or CXCL10. All
compounds blocking FAS at different key steps released CD4+
T cells from lactate-induced ‘‘stop migration signal’’ (Figure 6F).
Again, to further support our findings, we took advantage of
the Slc5a12 KO mouse and found that in response to lactate
migration response to CXCL10 was impaired (Figure 6G).
Overall, our findings indicate that lactate-induced inhibition
of CD4+ T cell response to migratory stimuli and retention in
the inflamed tissue is due to a metabolic adaptation to local
levels of lactate that entails reduced glycolysis and translocation
of HK2 to the outer membrane of mitochondria, with metabolic
fluxes diverted into NADPH-dependent de novo FAS
(Figure S6B).
Lactate/SLC5A12-Induced Metabolic Reprogramming
Is Operational in the CD4+ T Cell Infiltrated RA Synovium
To examine the lactate/SLC5A12-induced metabolic signaling
network in the clinical settings of RA, we took advantage of
the pathobiology of early arthritis cohort (PEAC). This is a cohort
of adults over the age of 18 manifesting early symptomatic in-
flammatory arthritis (<12months) andwho are naive to treatment
with conventional or biologic disease-modifying anti-rheumatic
drugs (DMARDs; http://www.peac-mrc.mds.qmul.ac.uk/index.
php). Synovial biopsies collected for this cohort were classified
according to histological pattern of synovitis (i.e., lymphoid,
myeloid, or fibroid; Pitzalis et al., 2013; Can˜ete et al., 2009) and
presence of ELSs. These are organized aggregates of T and B
cells that develop at sites of chronic inflammation and are asso-
ciated with more severe disease course and autoimmune re-
sponses as well as reduced response to therapy (Pitzalis et al.,
2013; Can˜ete et al., 2009). ELSs are rich in CD4+IL17A+ cells
that play a pivotal role in ELS formation and maintenance (Jones(D) Representative immunofluorescence images of untreated and lactate-treated
(blue). Scale bar, 10 mm.
(E) NADP+ and NADPH intracellular levels in CD4+ T cells (n = 5) treated with sodiu
as NADP+/NADPH ratio. Lactate-untreated CD4+ T cells (CN, dotted line) set to
(F) In vitro chemokinesis of activated CD4+ T cells in response toCCL20 (500 ng/m
with or without the metabolic drugs C75 (10 mM), TOFA (20 mM), and DHEA (20 m
(G) In vitro chemokinesis of activated CD4+ T cells (n = 4) from Slc5a12 WT or KO
(10 mM). Untreated CD4+ T cells (CN, dotted line) were set to 100.
Two-tailed Student’s t test (A), (B), and (E) or one-way ANOVA (F) and (G). Data exp
lactate + chemokine. See also Figure S6.
1066 Cell Metabolism 30, 1055–1074, December 3, 2019and Jones, 2016). Synovial biopsies were also classified by his-
tological analysis according to inflammatory score (Krenn score;
Krenn et al., 2002; Pitzalis et al., 2013) and expression of cell-
lineage CD4+ T cell gene modules. As expected, the synovial bi-
opsies with a lymphoid pathotype were also ELS positive and
showed the highest inflammatory score and degree of infiltration
by CD4+ T cells (Figure 7A).
In this cohort we analyzed the expression of groups of meta-
bolic genes on synovial biopsies by RNA sequencing (n = 87).
In the lymphoid pathotype, we found evidence of expected pat-
terns of Th17 differentiation genes, i.e., reduced FOXO1 and
increased IL17A, as well as of ELS genes (Figure 7A). When we
analyzed the metabolic genes, we found a downregulation of
glycolytic genes concurrent with an upregulation of PPP and
TCA cycle genes in the lymphoid pathotype as compared to
the other pathotypes (Figure 7A). Furthermore, we found a pos-
itive correlation between synovial SLC5A12 expression and
disease activity measured as DDAS28-CRP (Figure 7B). We
also found that DAS28-CRP correlates with IL17RA (Figure 7B)
as well as CXCL13, LTB, and FOXO1 (Figure S7A). Furthermore,
some key Th17 and metabolic genes described in our study
correlate, and in particular, FASN with SLC5A12 (Figure 7B) as
well as FASN with IL17RA, FASN with STAT3, and ACACA with
STAT3 (Figure S7B).
Overall, our data support a role for lactate/SLC5A12-induced
metabolic reprogramming in CD4+ T cells as a distinctive mech-
anism operational in the RA subset characterized by CD4+
T cell infiltration. In further support, we used a well-established
murine model of arthritis where the disease is induced by
subcutaneous injection of human glucose 6-phosphate isom-
erase and the inflammatory infiltrate into the joints is rich in
T cells (Schubert et al., 2004; Bruns et al., 2009; Iwanami et al.,
2008), hence resembling the human lymphoid RA. SLC5A12
Ab treatment reduced both clinical and histological scores of
arthritis as compared to the isotype control and showed a trend
effect superior to anti-TNF treatment (Figures 7C–7F)
DISCUSSION
Historically, lactate has been considered a waste product or at
best a biomarker in critical care. Yet in the past decades, it
was already shown to be a major substrate for oxidative phos-
phorylation (OXPHOS) in neurons, for gluconeogenesis in the
Cori cycle and for the synthesis of glycogen in the skeletal mus-
cle (Pellerin and Magistretti, 1994; Magistretti and Allaman,
2018; Cornell et al., 1973). Recent evidence further supports
lactate as a major carbon source for cellular metabolism both
in normal and cancerous tissues. Infusion of [U13C]-lactate
in fed and fasted mice, revealed extensive labeling of TCA cycleCD4+ T cells. Co-staining for hexokinase 2 (green), MitoTracker (red), and DAPI
m lactate (10 mM) for the indicated time points after 72-h activation and shown
1.
L; n = 4) or CXCL10 (300 ng/mL; n = 3) in the presence of sodium lactate (10mM)
M). Untreated CD4+ T cells (w/o CXCL10, dotted line) were set to 100.
mice in response to CXCL10 (300 ng/mL; 4 h) in the presence of sodium lactate
ressed asmean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001; #p% 0.05 versus
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Figure 7. SLC5A12 Expression Correlates with RA Disease Activity and Its Blockade Improves Clinical Scores in a Murine Model of (CD4+ T
Cells Joint-Enriched) Arthritis
(A) Heatmap showing RNA-sequencing expression of groups of metabolic genes differentially expressed (FDR < 0.05) between synovial biopsies (n = 87) from
early rheumatoid arthritis. Synovial biopsies were classified as positive or negative for ectopic lymphoid structures (ELS) by histological analysis. Upper tracks
show synovial histology inflammatory score (Krenn score), expression level of cell-lineageCD4+ T cell genemodules, ELS histology grouping and overall histology
pathotype (lymphoid, myeloid or fibroid).
(legend continued on next page)
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intermediates in all tissues (Hui et al., 2017; Faubert et al., 2017).
Strikingly, in lung and pancreatic tumors, the contribution of
lactate to the TCA cycle was greater than that of glucose (Fau-
bert et al., 2017).
Here, we showed that lactate accumulation in the inflamed
tissue contributes, together with activating and inflammatory
stimuli, to the upregulation of the sodium-coupled lactate
transporter SLC5A12 on human CD4+ T cells. SLC5A12 is
already upregulated by CD4+ T cells at the 12-h activation
time point of HC PBMCs and indeed this time point may
have the peak of SLC5A12 expression on the cell membrane.
Indeed, SLC5A12 expression on the membrane is reduced
at the subsequent 24- and 48-h time points. These data sug-
gest that a longer kinetic may not be required. Yet, the 48-h
time point in most of our experiments is justified by the fact
that we need to allow time for cells to respond functionally
to lactate.
SLC5A12-mediated lactate uptake by human CD4+ T cells
initiated an anabolic response leading to de novo FAS and
involved the translocation of PKM2 in the nucleus. Both
mechanisms contributed to the activation of downstream
STAT3 transcription factors. Such integration between meta-
bolism and signaling modules led to the plastic reshaping of
the CD4+ T effector phenotype within the inflamed tissue.
Our data are in line with Yabu et al. who showed that lactic
acid enhances the production of IL23/IL17 by CD4+ T cells,
acting as a pro-inflammatory signal (Yabu et al., 2011). However,
the mechanisms were not known. In line with lactate being a
major fuel for the TCA cycle (Hui et al., 2017; Faubert et al.,
2017), we observed an increase in citrate and acetyl-CoA
levels upon exposure of activated CD4+ T cells to lactate at con-
centrations as in the chronic inflamed site. Acetyl-CoA is pro-
duced by the breakdown of both glucose (by glycolysis) and
fatty acids (by FAO). It then enters the TCA cycle in themitochon-
drion and forms citrate by reacting with oxaloacetate. Citrate
can be exported to the cytosol, where it may be converted
back to acetyl-CoA and then serve as a substrate for FAS
through carboxylation in to malonyl-CoA by ACC, the first
committed step in the synthesis of fatty acids. Indeed, after
lactate treatment, we detected activation of ACC, which in line
with our data has been shown to be indispensable for IL17
production (Berod et al., 2014; Endo et al., 2015).
Our in vitro data were further extended to disease pathobi-
ology by RNA sequencing analysis showing a metabolic dysre-
gulation within the synovium of the subset of RA patients, which
is characterized by CD4+ T cell infiltration (40% of total
patients). In particular, these patients displayed a low expres-
sion of glycolysis and increased levels of TCA cycle and PPP
related genes, in line with data published by the Weyand’s(B) Synovium SLC5A12 transcript positively correlates with delta disease activit
baseline and DAS28-CRP at 6 months and FASN transcript; also shown is the p
transcript (n = 87). Correlation analyses performed using Spearman’s correlation
(C–F) Arthritis score in mice treated with the indicated antibodies versus controls.
no clinical signs of arthritis; a score of 1 for each of the toes, pad, and ankle indicat
Representative images of the paws at day 21 post-immunization showing the effe
the SLC5A12 isotype control antibody (D). Histological score in pads of mice
assessment of an H&E slide acquired from the representative group, n = 19–24 s
(arrows) in the pad of mice treated with SLC5A12 Ab as compared to isotype c
represent mean ± SD. *p% 0.05; **p% 0.01; #p% 0.05. See also Figure S7.
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2016; Shen et al., 2017).
In contrast to its splice variant PKM1, which is constitutively
expressed in most adult tissues, PKM2 is allosterically activated
in a feed-forward regulatory loop by an upstream glycolytic
metabolite, fructose-1,6-bisphosphate (FBP), and is susceptible
to inhibition by growth factor signaling through interaction with
phospho-tyrosine containing proteins. These properties of
PKM2 allow proliferating cells to divert glucose into anabolic
pathways emanating from glycolysis in order to meet the
increased biosynthetic demands of proliferation. Association
of PKM2 subunits into homo-tetramers is required for optimal
enzymatic activity (Eigenbrodt et al., 1992). Both reduced FBP
and increased ROS cause decreased PKM2 activity (Anastasiou
et al., 2011). Incidentally, lactate uptake causes both these
effects. PKM2 inhibition is able to divert glucose into the PPP
and thereby generate NADPH (Le Goffe et al., 2002), which in
turn provides reducing equivalents for detoxification of ROS
by increasing reduced glutathione (GSH) and hence allowing
cells to withstand oxidative stress. The small-molecule PKM2
activator DASA-10 (NCGC00181061, a substituted N,N0-diary-
lsulfonamide) prevented inhibition of PKM2 by H2O2 (Anastasiou
et al., 2011). PKM2 has been investigated in atherosclerotic
coronary artery disease (CAD) and RA patient-derived macro-
phages. Here, the increased glucose uptake and glycolytic
flux due to inflammation fuel the generation of mitochondrial
ROS, which in turn promote the destabilization of the PKM2
tetramer, favoring its dimerization and subsequent nuclear
translocation. Nuclear PKM2 functions as a protein kinase that
phosphorylates the transcription factor STAT3, thus boosting
IL6 and IL1b production (Shirai et al., 2016; Weyand et al., 2017).
In line with these findings, we observed an increase of PKM2
nuclear translocation with concomitant enhanced STAT3
phosphorylation upon treatment of activated CD4+ T cells with
lactate. STAT3 is implicated in Th17 differentiation (Yang et al.,
2007) and interestingly, the inhibition of PKM2 nuclear translo-
cation with DASA was able to reduce lactate-mediated IL17
production.
Similarly, lactate dehydrogenase A (LDHA) enzymatic activity
was recently shown to be necessary to sustain IFNg production
by CD4+ T cells via induced aerobic glycolysis (Peng et al.,
2016). Genetic deletion of LDHA in CD4+ T cells significantly
reduced glucose consumption and promoted a shift toward
oxidative metabolism, as well as the reduction of IFNg expres-
sion. The decrease in IFNg transcripts was due to reduced his-
tone acetylation. Acetyl-CoA serves as a substrate for lysine
acetyltransferases (KATs), which catalyze the transfer of acetyl
groups to the epsilon-amino groups of histone lysines and
many other proteins. Fluctuations in the concentration ofy score (D DAS28-CRP) calculated as the difference between DAS28-CRP at
ositive correlation between the inflammatory score DAS28-CRP with IL17RA
coefficients.
Arrows indicate days at which antibodies were injected. A score of 0 indicates
es swelling and redness. Maximum score for each paw is 7 (n = 6 per group; C).
cts (i.e., swelling and redness) of treatment with SLC5A12 Ab as compared to
subjected to different treatments, as shown (each dot corresponds to the
lides/group; E). IHC with haematoxylin counterstain showing immune infiltrate
ontrol antibody-treated mice (F). Two-tailed Student’s t test (C) and (E). Data
acetyl-CoA, reflecting the metabolic state of the cell, are trans-
lated into dynamic protein acetylation that regulates a variety of
cell functions, including transcription, replication, DNA repair,
cell cycle progression, and aging (Shahbazian and Grunstein,
2007). In the absence of LDHA, the increase in the rate of the
TCA cycle necessary to compensate the drop in glycolysis
did not allow the export of acetyl-CoA from the mitochondria
to the cytosol, thus reducing the pool of acetyl groups available
for histone acetylation. These data demonstrate the regulation
of INF-g production in Th1 cells by lactate metabolism through
a fine-tuned epigenetic mechanism of histone acetylation
coupled to cellular metabolism (Peng et al., 2016).
Furthermore, N-Terminal acetylation of cellular proteins initi-
ates specific protein degradation processes (Hwang et al.,
2010). We did not observe increased lysine acetylation of cyto-
solic proteins upon cell exposure to lactate, suggesting this
may not be the mechanism responsible for the reduced
expression of glycolytic enzymes we observed in the presence
of lactate, which may instead be due to reduced pathway
usage consequent to NADH build up in the cell, as we have
shown in line with literature. Moreover, citrate is a known
inhibitor of glycolysis and its accumulation might have been
responsible for the inhibition of glycolysis observed (Newsholme
et al., 1977).
In contrast, the immune cell response to lactate in the tumor
microenvironment is quite different from that seen in the context
of chronic inflammation. Recent studies have reported the ability
of tumor-derived lactate to suppress the immune response
against the tumor itself, thus creating an environment permissive
to the tumor growth (Brand et al., 2016; Angelin et al., 2017; Co-
legio et al., 2014).
Lactate accumulation in the inflamed tissue also caused CD4+
T cell retention at the site of inflammation, as a consequence of
impaired cell motility caused by reduced glycolysis and
enhanced FAS. In addition to a reduced glucose flux through
glycolysis, several glycolytic enzymes, including HK, were
decreased upon cell exposure to lactate in a time-dependent
manner. HK catalyzes the first committed step of glucose meta-
bolism. Glucose entering the cell through glucose transporters
(GLUTs) is phosphorylated by HK to produce G6P. The two
most common isoforms, HK1 and HK2, have overlapping
tissue expression, but different subcellular distributions, with
HK1 associated mainly with mitochondria and HK2 shuttling
between mitochondrial and cytoplasmic compartments. HK2
binds to the voltage-dependent anion channel (VDAC), an outer
mitochondrial membrane protein, which interacts with the
adenine nucleotide translocase (ANT), forming a contact site
between the outer and inner mitochondrial membranes (Fiek
et al., 1982; Vyssokikh and Brdiczka, 2003).
Accordingly, we found increased mitochondrial localization of
HK2 upon lactate treatment. We also found a reduction of
NADP+/NADPH ratio, suggesting a shunt toward PPP and
anabolic metabolism. Moreover, mitochondria-associated HK2
has a pro-survival function via antagonizing apoptotic Bcl-2
family proteins and thereby protects cells from apoptosis (Pas-
torino et al., 2002). This may be a mechanism that allows CD4+
T cell survival in lactate-rich environments.
Our data fit with RA naive CD4+ T cells displaying low
basal glycolysis due to a deficiency in 6-phosphofructo-2-ki-nase/fructose-2,6-bisphosphatase (PFKFB3). This caused a
shunt of glucose-6-phosphate (G6P) toward the pentose
phosphate pathway (PPP) with generation of NADPH equiva-
lents and altered activation of ataxia telangiectasia mutated
(ATM), a key enzyme in the control of cell cycle. Such alter-
ations resulted in a high capacity of proliferation by RA CD4+
T cells and a switch to pro-inflammatory subsets such as Th1
and Th17 and chronic inflammation (Yang et al., 2013, 2016).
ATPlow pyruvatelow NADPHhigh RA CD4+ T cells also displayed
increased FAS and consequent deposition of cytoplasmic lipid
droplets. This resulted in the upregulation of the podosome
scaffolding protein TKS5. TKS5hi RA CD4+ T cells spontaneously
formed actin- and cortactin-rich membrane ruffles, which em-
powered them to penetrate into non-lymphoid tissue and
establish inflammatory infiltrates. All these effects were abol-
ished by FAS inhibition (Shen et al., 2017).
Building on these results, our data suggest that FAS is not
only responsible for increased infiltration of the inflamed site by
CD4+ T cells, but also for their retention in the site, together
with reduced glycolysis, once they have reached it. De novo
FAS is required for Th17 differentiation and pharmacologic
inhibition of acetyl-CoA carboxylase, a key enzyme in FAS,
was able to delay the disease and to reduce the severity of
experimental autoimmune encephalomyelitis (EAE), (Berod
et al., 2014). Hence, inhibiting FAS and/or promoting glycolysis
may support resolution of inflammation.
If RA CD4+ T cells display a deficit in glycolysis, synovial RA
fibroblasts are highly glycolytic. Indeed, glucose deprivation
or glycolytic inhibitors such as 2-deoxy-D-glucose (2-DG), bro-
mopyruvate (BrPa) and 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-
1-one, impaired cytokine secretion, proliferation, and migration
by synovial fibroblasts as well as disease severity in a mouse
model of arthritis (Garcia-Carbonell et al., 2016). In line with
this evidence, the inducible isoform of hexokinase, HK2, which
catalyzes the phosphorylation of glucose to G6P—the first
committed step in glucose metabolism—was found highly
expressed by RA as compared to OA synovial fibroblasts. Inter-
estingly, after HK2 silencing, RA fibroblasts were less invasive
while the overexpression of HK2 enhanced the levels of MMP,
IL6, and IL8 other than their migratory capabilities (Bustamante
et al., 2018). Altered metabolism in RA fibroblasts has also
been associated with the hypoxic microenvironment typical of
the inflamed sites. Specifically, it was found that hypoxia
induced a downregulation of mitochondrial respiration and an
increase of glycolysis in RA fibroblast, which in turn promoted
synovial invasive mechanisms (Biniecka et al., 2014). Hence, it
is tempting to speculate that synovial fibroblasts produce large
amounts of lactate in the arthritic synovium, which infiltrating
CD4+ T cells have to face and adapt to. Here, we have described
how they adapt to such condition.
Interestingly, the response to lactate by CD4+ T cells is medi-
ated by a specific sodium lactate transporter, SLC5A12, which
seems to be a major lactate transporter in these cells, unlike
other immune cells, i.e., macrophages. We previously described
in Haas et al. (2015) that CD4+ T cells express SLC5A12 but
not SLC16A1 (MCT1). Here, we show that when we interfere
with the carrier function of SLC5A12 in CD4+ T cells we see an
impairment of some of their effector functions, namely migration
and IL17 production. In comparisons, we do not see anyCell Metabolism 30, 1055–1074, December 3, 2019 1069
effects of blocking SLC5A12 in macrophages—although they do
express it—when we assess their migratory response to lactate
(Figure 5B). This suggests that SLC5A12 may not be a major
lactate transporter in macrophages and/or they may be able to
use others, unlike what we observe in CD4+ T cells.
A selective expression of lactate transporters by immune
cells may orchestrate their spatial distribution inside the inflamed
tissue as well as affect their functional response (Ene-Obong
et al., 2013; Haworth et al., 2008; Olloquequi et al., 2010).
Thus, modulating selective T cell subsets via targeting specific
lactate transporters may provide novel therapeutic tools to
reduce inflammation as well as contributing to a better under-
standing of the pathogenesis of chronic inflammation. In this
respect, our findings show that SLC5A12 does not particularly
discriminate among CD4+ T cell subsets, which is what we
would expect since we observe 40% SLC5A12+ CD4 T cells
while only a small fraction of activated CD4+ T cells are normally
IL-17 producers. It remains our message that lactate promotes
IL-17 responses via metabolic rewiring downstream of
SLC5A12-mediated lactate uptake and we have elucidated
the mechanisms for this response. It also remains to be as-
sessed whether lactate may modulate Th1 and/or Tfh
responses.
Altogether this evidence supports a role for lactate as a
major signaling molecule in its own right, able to operate the
plastic shift of the immune response within the diseased site,
whether in the tumor or the chronic inflammatory environment.
In the site of inflammation, such as the inflamed synovium in
RA, lactate seems to act as an amplifier of inflammation leading
to the entrapment of CD4+ T cells and stimulation of inflamma-
tory cytokines. In further support to the signaling activity of
lactate, a receptor of lactate, GPR81, has been identified and
involved in the regulation of lipolysis (Liu et al., 2009) and cancer
cell survival (Roland et al., 2014). Lactate binding to GPR81 re-
sulted in the upregulation of PD-L1, causing the suppression of
the effector function of T cells in co-culture experiments (Feng
et al., 2017).
Th17 CD4+ T cells play an important role in RA, multiple
sclerosis, and psoriasis (Patel and Kuchroo, 2015). Rising levels
of circulating Th17 cells and IL17 were observed in patients with
an inadequate response to anti-TNF-a therapy (Chen et al.,
2011). Despite several studies revealed the importance of
IL17 in the pathogenesis of RA, clinical trials with IL17 blocking
agents in RA have not reached striking results so far (Kugyelka
et al., 2016), thus other targets are needed. This can be in
part due to the heterogeneity of RA in terms of pathogenesis
and histological patterns of synovitis (Pitzalis et al., 2013). IL17
and IL17R family members show a high variability in the
expression in individual patients (Van Baarsen et al., 2014).
Therefore, it is not surprising that the blockade of IL17A or its
receptor with monoclonal antibodies did not lead to complete
disease remission so far. Currently it is more likely that IL17 tar-
geting agents could be used to complement and/or augment
current therapies (Kugyelka et al., 2016). Moreover, IL17-
signaling cascade is a complex system. Indeed, it consists of 6
members with 5 known receptors, thus widening the frontier
for the development of new blocking and/or modifying agents,
which might offer exciting new treatments in autoimmunity. For
this reason, targeting the IL17 axis at different levels (i.e., Th171070 Cell Metabolism 30, 1055–1074, December 3, 2019differentiation and signaling), including blocking SLC5A12, may
provide new therapeutic avenues for Th17-mediated inflamma-
tory disorders.
Limitations of Study
Immunization with human recombinant G6PI or with the im-
mune-dominant peptide G6PI325-339 was shown to induce an
inflammatory polyarthritis which can be modulated by therapeu-
tic interventions aimed at targeting T cell function (i.e., by
inducing a switch in the balance between Th1/Th17 cells and
Tregs; Shubert et al., 2004; Yoshida et al., 2016; Hirota et al.,
2017). Based on these observations and our findings of a domi-
nant effect of SLC5A12 on CD4+ T cells, we chose this experi-
mental model of arthritis to test the effect of blocking
SLC5A12. Nevertheless, a caveat to our findings is that the
beneficial effects of targeting SLC5A12 may be due at least in
part to its effects of macrophages and/or B cells. This could be
further tested in other models of arthritis, such as collagen-
induced arthritis. Anyhow, a previous demonstration of the
functional relevance of SLC5A12 blockade was provided by
us, using a zymosan model of peritonitis (Haas et al., 2015).
Furthermore, intra-articular injections are required in our
model currently to achieve high enough concentration of the
antibody within the joint as the effect of anti-SLC5A12 is elicited
at the site of inflammation where high levels of lactate are pre-
sent. This procedure would not lead to a biological effect
systemically because a single dose of the antibody at the con-
centration used would be too low to achieve sufficient blood
concentrations to enter efficiently other joints and/or organs.
The same can be said for the control antibodies. Thus, we would
not expect any systemic effect clinically. Additionally, we used
the contralateral joint as control as this is routinely used in
experimental arthritis, offering the advantage of minimizing the
inherent variability in the severity of arthritis observed among
different animals and allows direct comparison of data (Chen
et al., 2015; Min et al., 2013; Mor-Vaknin et al., 2017). Regardless
of these caveats to our current study, to advance in the pre-clin-
ical space, our next steps will be to generate and characterize
recombinant murine and humanized mAbs targeting SLC5A12,
which we will then administer systemically
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Cell Signaling Technology Cat#11818; RRID:AB_2687505
Phospho-AMPKa (Thr172) (40H9) Rabbit mAb Cell Signaling Technology Cat#2535
Phospho-Stat1 (Tyr701) (58D6) Rabbit mAb Cell Signaling Technology Cat#9167; RRID:AB_10859888
Phospho-Stat3 (Tyr705) (D3A7) XP Rabbit mAb Cell Signaling Technology Cat#9145; RRID:AB_2491009
PKM1/2 (C103A3) Rabbit mAb Cell Signaling Technology Cat#3190; RRID:AB_2163695
Rabbit polyclonal anti-PFK Novus Biologicals NEP1-37473
RORgt mouse antibody (clone Q21-559) BD Biosciences Cat#563424
SLC5A12 Antibody Atlas Antibodies HPA060904
SLC5A12 Antibody Abcam Ab107749; RRID:AB_10864245
SLC5A12 Antibody Novus Biologicals NBP2-49322
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SLC5A12 monoclonal (clone 10E11) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 3C7) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 4G2) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 6E1) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 7C1) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 9G4) Aldevron GmbH N/A
SLC5A12 monoclonal (clone 9G7) Aldevron GmbH N/A
Stat1 (D1K9Y) Rabbit mAb Cell Signaling Technology Cat#14994; RRID:AB_2737027
Stat3 (D3Z2G) Rabbit mAb Cell Signaling Technology Cat#12640; RRID:AB_2629499
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VDAC (D73D12) Rabbit mAb Cell Signaling Technology Cat#4661; RRID:AB_10557420
b-Actin (13E5) Rabbit mAb Cell Signaling Technology Cat#4970
Biological Samples
Blood obtained from healthy anonymous adult donors N/A N/A
Mouse paw tissue N/A N/A
Synovial fluids obtained from rheumatoid arthritis
patients
N/A N/A
Synovial tissues obtained from rheumatoid arthritis
patients
N/A N/A
Tonsils from subjects undergoing tonsillectomy N/A N/A
Chemicals, Peptides, and Recombinant Proteins
AICAR Merck Cat#A9978
C75 Santa Cruz Biotechnology SC-202511
DASA Merck Cat#550602
DHEA Cayman Cat#15728
Etomoxir Merck Cat#236020
FCCP Merck Cat#C2920
Histopaque 1077 Sigma-Aldrich Cat#10771
Leukocyte Activation Cocktail BD Biosciences Cat#550583
Lymphoprep Stemcell Technologies Cat#07801
Oligomycin Merck Cat#495455
Palmitate Sigma-Aldrich P9767
Sodium L-lactate Sigma-Aldrich Cat#71718
TOFA Santa Cruz Biotechnology SC-200653
Critical Commercial Assays
Citrate Colorimetric/Fluorimetric Assay Kit BioVision Cat#K655-100
EasySep Human CD4+ T Cell Isolation Kit STEMCELL Technologies Cat#17952
EasySep Mouse CD4+ T Cell Isolation Kit STEMCELL Technologies Cat#19852
Free Fatty Acid Assay Kit – Quantification abcam Cat#ab65341
H2DCFDA ThermoFisher Scientific Cat#D399
Human IFN gamma ELISA Ready-SET-Go! Kit fisherscientific Cat#15541107
Human IL-17A (homodimer) ELISA Ready-SET-
Go! Kit
fisherscientific Cat#15501077
Mitochondria Isolation Kit for Cultured Cells ThermoFisher Scientific Cat#89874
NAD+/NADH Quantification Colorimetric Kit BioVision Cat#K337-100
NADP/NADPH Assay Kit Abcam Cat#ab65349
Nuclear Extraction Kit abcam Cat#ab113474
PicoProbeTM Acetyl CoA Fluorimetric Assay Kit BioVision Cat#K317-100
Zombie NIR Fixable Viability Kit BioLegend Cat#423105
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Deposited Data
Raw data files for RNA sequencing ArrayExpress https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-6141
Experimental Models: Cell Lines
Human: MCs from tonsils (primary) N/A N/A
Human: PBMCs from healthy controls (primary) N/A N/A
Human: PBMCs from rheumatoid arthritis patients
(primary)
N/A N/A
Human: SFMCs from rheumatoid arthritis patients
(primary)
N/A N/A
Mouse: CD4+ T cells from Slc5a12 WT or KO mice
(primary)
N/A N/A
Experimental Models: Organisms/Strains
Mouse: SLC5A12 KO (Allele: Slc5a12em1(IMPC)Wtsi) Sanger Institute N/A
Oligonucleotides
BCL6 forward primer: 5’-
CGAATCCACACAGGAGAGAAA-3’
Invitrogen 347017 U4335 (B08)
BCL6 reverse primer: 5’-
ACGCGGTATTGCACCTTG-3’
Invitrogen 347017 U4335 (B09)
CXCR5 forward primer: 5’-
GCTAACGCTGGAAATGGA-3’
Invitrogen 347017 U4335 (C04)
CXCR5 reverse primer: 5’-
GCAGGGCAGAGATGATTT-3’
Invitrogen 347017 U4335 (C05)
Foxo1 forward primer: 5’-
AGGGTTAGTGAGCAGGTTACAC-3’
Invitrogen 347017 U4335 (C02)
Foxo1 reverse primer: 5’-
TGCTGCCAAGTCTGACGAAA-3’
Invitrogen 347017 U4335 (C03)
Foxp3 forward primer: 5’-
CTGACCAAGGCTTCATCTGTG-3’
Invitrogen 347017 U4335 (A06)
Foxp3 reverse primer: 5’-
ACTCTGGGAATGTGCTGTTTC-3’
Invitrogen 347017 U4335 (A07)
GAPDH forward primer: 5’-
TCCTCTGACTTCAACAGCGA-3’
Invitrogen 347017 U4335 (B02)
GAPDH reverse primer: 5’-
GGGTCTTACTCCTTGGAGGC-3’
Invitrogen 347017 U4335 (B03)
IFNg forward primer: 5’-
GGCATTTTGAAGAATTGGAAAG-3’
Invitrogen 347017 U4335 (B04)
IFNg reverse primer: 5’-
TTTGGATGCTCTGGTCATCTT-3’
Invitrogen 347017 U4335 (B05)
IL10 forward primer: 5’-
ACCTGCCTAACATGCTTCGAG-3’
Invitrogen 347017 U4335 (B10)
IL10 reverse primer: 5’-
CCAGCTGATCCTTCATTTGAAAG-3’
Invitrogen 347017 U4335 (B11)
IL17A forward primer: 5’-
TGTCCACCATGTGGCCTAAGAG-3’
Invitrogen 347017 U4335 (A08)
IL17A reverse primer: 5’-
GTCCGAAATGAGGCTGTCTTTGA-3’
Invitrogen 347017 U4335 (A09)
IL22 forward primer: 5’-
TCCAGAGGAATGTGCAAAAG-3’
Invitrogen 347017 U4335 (D07)
IL22 reverse primer: 5’-
ACAGCAAATCCAGTTCTCCAA-3’
Invitrogen 347017 U4335 (D08)
IL6 forward primer: 5’-
AGTGAGGAACAAGCCAGAGC-3’
Invitrogen 347017 U4335 (E07)
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
IL6 reverse primer: 5’-
GTCAGGGGTGGTTATTGCAT-3’
Invitrogen 347017 U4335 (E08)
PD1 forward primer: 5’-
ACCTGGGTGTTGGGAGGGCA-3’
Invitrogen 347017 U4335 (B12)
PD1 reverse primer: 5’-
GGAGTGGATAGGCCACGGCG-3’
Invitrogen 347017 U4335 (C01)
RORgt forward primer: 5’-
CCTGGGCTCCTCGCCTGACC-3’
Invitrogen 347017 U4335 (A04)
RORgt reverse primer: 5’-
TCTCTCTGCCCTCAGCCTTGCC-3’
Invitrogen 347017 U4335 (A05)
SLC5A12 forward primer: 5’-
GTGTGCTGTCTTCTCTGGCT-3’
Eurofins MWG Operon H680 31-3128-11/12
SLC5A12 reverse primer: 5’-
GCCACAAAAAGTCCTGGCAG-3’
Eurofins MWG Operon H680 31-3128-12/12
TGFb forward primer: 5’-
AGCGACTCGCCAGAGTGGTTA-3’
Invitrogen 347017 U4335 (A10)
TGFb reverse primer: 5’-
GCAGTGTGTTATCCCTGCTGTCA-3’
Invitrogen 347017 U4335 (A11)
B-Actin forward primer: 5’-
AGTTGCGTTACACCCTTTCTTG-3’
Invitrogen 347017 U4335 (A12)
B-Actin reverse primer: 5’-
TCACCTTCACCGTTCCAGTTT-3’
Invitrogen 347017 U4335 (B01)
Software and Algorithms
GraphPad Prism 7 GraphPad Software, Inc http://www.graphpad.com/scientific-
software/prism/
FlowJo 7.6.5 Tree Star www.flowjo.com
ImageJ ImageJ https://imagej.nih.gov/ij/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Claudio
Mauro (c.mauro@bham.ac.uk). Mouse lines used in this study are available at INFRAFRONTIER/EMMA (www.infrafrontier.eu),
(Allele: Slc5a12em1(IMPC)Wtsi). There are restrictions to the availability of SLC5A12 monoclonal antibodies due to intellectual prop-
erty and ongoing patenting.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
Blood, synovial fluids and synovial tissues were obtained from the same cohort of rheumatoid arthritis (RA) patients diagnosed
according to the revised American College of Rheumatology (ACR) criteria (Aletaha et al., 2010). Demographic and clinical charac-
teristics of the study cohort are presented in Table S1.
Healthy individuals, age and sex matched with RA patients (Table S1), were recruited through NHS Blood and Transplant service.
Individuals with cancer, infections or other inflammatory comorbidities were excluded. Written informed consent was obtained by all
participants according to ethical approval from National Research Ethics Service Committee London (LREC07/Q0605/129).
For RNA sequencing analysis, mRNA was extracted from synovial tissue samples obtained by ultrasound-guided biopsy from
patients with early active RA (< 12 months’ time) who were naı¨ve-to-treatment with disease-modifying anti-rheumatic drugs
(DMARDs) (n = 87). Patients were enrolled in the Pathobiology of Early Arthritis Cohort (PEAC, details at http://www.peac-mrc.
mds.qmul.ac.uk/index.php) at the Centre for Experimental Medicine and Rheumatology at Queen Mary University of London
(REC 05/Q0703/198, London, UK), as previously described (Kelly et al., 2015; Humby et al., 2019; Lewis et al., 2019). All patients
belonging to this cohort underwent baseline ultrasound-guided biopsy on the most inflamed accessible joint. Afterward, patients
started treatment with conventional DMARDs (methotrexate, leflunomide and/or sulphasalazine and/or hydroxychloroquine and/
or corticosteroids). The response to treatment was evaluated at six months according to DAS28-CRP (Fransen, and van Riel, 2009).e4 Cell Metabolism 30, 1055–1074.e1–e8, December 3, 2019
Cell Isolation and Culture
Peripheral blood mononuclear cells (PBMCs) from healthy controls (HC) and paired PBMCs and synovial fluid mononuclear cells
(SFMCs) were obtained from RA patients. PBMCs and SFMCs were isolated by density gradient centrifugation [lymphoprep
(StemCell Technologies) and histopaque 1077 (Sigma-Aldrich), respectively]. Cells (2 3 106/mL) were cultured in 48-well plates
(37C, 5% CO2) in medium (RPMI 1640 - ThermoFisher) supplemented with 10% FBS (ThermoFisher) or 10% autologous blood
serum or 10% RA synovial fluid and activated with 0.2mg/ml anti-CD3 monoclonal antibody (CD3mAb, EBioscience) or left non-acti-
vated, according to well-established protocols (Pucino et al., 2016; Landegren et al., 1984; Van Wauwe et al., 1980).
For the experiments with human tonsils, tissues were mashed through a cell strainer and mononuclear cells (MCs) were isolated.
Cells were cultured (2 3 106/ml, 37C, 5% CO2) in RPMI 1640 plus 10% FBS and activated with 0.2mg/ml anti-CD3 mAb (Thermo
Fisher Scientific) or left non-activated.
All samples from HC (PBMCs and tonsils) were gender- and age- matched with samples (SFMCs, PBMCs) from RA patients (for
details see Table S1).
CD4+ T cells were purified from human PBMCs or MCs, or from spleen and lymph nodes of Slc5a12 WT or KO female mice by
negative selection using a magnetic cell separation (EasySep, Stem Cell Technology), cultured in RPMI 1640 plus 10% FBS
(37C, 5% CO2) and then stimulated for 3 days in the presence of anti-CD3 and anti-CD28 mAbs coated Dynabeads (0.1 beads
per cell; Thermo Fisher Scientific).
Mouse Models
We thank the Wellcome Trust Sanger Institute Mouse Genetics Project (Sanger MGP) and its funders as well as INFRAFRONTIER/
EMMA (www.infrafrontier.eu), for accepting our gene nomination for Slc5a12, and for generating and providing the Crispr/Cas9
mutant mouse line (Allele: Slc5a12em1(IMPC)Wtsi) in the C57BL/6N background (White et al., 2013; Skarnes et al., 2011; Bradley
et al., 2012; Pettitt et al., 2009). All procedures were consented by the UK Home Office and animals were sacrificed following an
accepted Schedule 1 method.
DBA/1 female mice purchased fromCharles River were immunized s.c. with 20mg human hG6PI synthetic peptide (hG6PI325-339;
ThermoFisher Scientific) in CFA (Sigma-Aldrich). The indicated amount of peptide was mixed with CFA in a 1:1 ratio (v/v) and emul-
sified by sonication. For induction of arthritis, 100ml of the emulsion was injected subcutaneously at the base of the tail. At day 7 – a
time point at the onset of the disease – and 11 post-induction, mice were left untreated or treated with intra-articular injection of 20ml
of 0.1mg/ml antibody into the rear paws; Infliximab (Remicade, Janssen Biologics), anti-TNF (TN3-19.12, BD Bioscience), anti-
SLC5A12 (Atlas Antibodies), Iso-TNF (BD biosciences) and Iso-SLC5A12 (Atlas Antibodies). Specific antibody and the corresponding
isotype control were injected into the right or left back paw of the same mouse. The development of disease was monitored daily by
visually assessing the arthritis score. A score of 0 indicates no clinical signs of arthritis; a score of 1 for each of the fingers, pad and
ankle indicates swelling and redness. Maximum score for each paw is 7. A trained observer who was blinded to the immunization
status of the mice performed the scoring.
All micewere group-housed andmaintained under SPF health/immune status in individually ventilated cages with standard enrich-
ment. Mice were housed in a temperature (24C) and humidity-controlled room on a 12 h light/dark cycle (lights on 7:00) with ad li-
bitum access to water and food.
METHOD DETAILS
Flow Cytometry
In order to assess SLC5A12 expression on different immune cell types, we stained PBMCs or tonsil MCs or RA SFMCs with Live/
Dead (ZOMBIE/NIR, fixable viability dye, 1:1000, BioLegend) for 15 minutes at room temperature protected from light to allow detec-
tion and exclusion of dead cells from the analysis. Without washing, cells were then stained with BV711–labelled anti–CD4 (clone
RPA-T4, 1:100), PE/Dazzle–labelled anti–CD8 (clone HIT8a, 3:1000), FITC–labelled anti–CD14 (clone 63D3, 1:100), PeCy7–labelled
anti–CD19 (clone HIB19, 1:100). Rabbit anti-SLC5A12 unconjugated primary antibody (4:1000, HPA060904 – Atlas Antibodies) was
added after fixing and permeabilizing cells (fixation-permeabilization buffer; eBioscience) for 30 minutes followed by Alexa Fluor-555
goat anti-rabbit (1:1000, Invitrogen) secondary antibody. Polyclonal rabbit IgG (DAKO) was used as isotype control.
To assess SLC5A12 expression on T cell subsets identified on the basis of transcription factors expression or cytokines produc-
tion, healthy donors PBMCs were activated for 48h and incubated with Leucocyte Activating cocktails (BD) for the last 3 hours. Cells
were first stained for Live/Dead Zombie for 15 minutes at room temperature protected from light, washed and incubated for 10 mi-
nutes with human Fc TruStain FcX (BioLegend, 5:100) to block Fc receptors (CD16, CD32, CD64) and avoid non-specific binding.
Surface antigens were stained with BV510-labelled anti-CD14 (clone 63D3, 1:100), BV510-labelled anti-CD19 (clone HIB19,
1:100), PE/Dazzle 594-labelled anti-CD4 (clone A161A1, 1:100), APC Cy7-labelled anti-CD8 (clone SK1, 1:100), BV605-labelled
anti-CXCR5 (J252D4, 5:100), PECy7-labelled anti-ICOS (clone C398.4A, 1:100), PerCpCy5.5-labelled anti-PD1 (clone EH12.2H7,
1:100), PECy5-labelled anti-CD25 (clone BC96, 1:100) (BioLegend). Cells were then fixed, permeabilized (fixation-permeabilization
buffer; eBioscience) and stained first with Pacific Blue-labelled anti-Tbet (clone 4B10, 2:100), PE-labelled anti-Foxp3 (clone 206D,
2.5:100), BV711-labelled anti-IL17A (clone BL168, 5:100), BV785-labelled anti-IFNg (clone 4S.B3, 3:100), Alexa647-labelled anti-
IL21 (clone 3A3-N2, 3:100) (BioLegend) and BV650-labelled anti-RORgt (clone Q21-559, 2:100) (BD Biosciences). Rabbit anti-Cell Metabolism 30, 1055–1074.e1–e8, December 3, 2019 e5
SLC5A12 unconjugated primary antibody (0.4:100, HPA060904 – Atlas Antibodies) was then added for 30 minutes followed by Alexa
Fluor-555 goat anti-rabbit (1:1000, Invitrogen) secondary antibody.
Cells were acquired using a LSR Fortessa II (BD Biosciences) flow cytometer and analyzed with FlowJo version 7.6.5 software. All
monoclonal antibodies were from Biolegend.
Immunofluorescence, Immunohistochemistry, and Confocal Microscopy
For SLC5A12 single and double (with CD4, CD8, CD20 or CD68) immunofluorescence, after antigen retrieval (S2367, Dako; 45 mi-
nutes) and block of non-specific binding (1 hour hour), paraffin-embedded tonsil tissue sections were incubated for 1 hour hour with
anti-SLC5A12 Ab (1:50, Novus Biologicals) and then overnight at 4C with anti-CD4, anti-CD8, anti-CD20 or anti-CD68 (1:50, Dako).
The following day, slides were washed in PBS and incubated with fluorochrome-conjugated secondary antibodies (1:300, Invitrogen,
Eugene, Oregon, USA). The slides were then washed in PBS for up to 5 minutes, mounted in fluorescence mounting medium
(DakoCytomation) containing 1 mg/ml DAPI, and examined by Olympus IX81 fluorescence microscope. The list of primary and sec-
ondary antibodies is shown in Key Resources Table.
For the intracellular detection of HK2, human CD4+ T cells cultured on glass coverslips were incubated for 5 minutes with 300 nM
mitotracker deep red FM (ThermoFisher Scientific) at 37C in 5% CO2. After the incubation period, cells were washed twice and
fixed/permeabilized in permeabilization/fixation buffer (Bioscience) overnight at 4C. After washing with PBS, cells were incubated
with the primary antibodies against anti-HK2 (dilution 1:200, Cell Signaling Technology) for 1 hour at room temperature followed by
30 minutes incubation with 1:200 secondary Alexa Fluor 555 conjugated goat anti-rabbit (Invitrogen). Alexa Fluor 488 phalloidin
(ThermoFisher) for the actin staining was also added at this stage. One million cells resuspended in 100 ml PBS were counterstained
with DAPI to detect nuclei, spun in the cytospin (250 rpm for 5minutes) to allow the attachment to the coverslips and thenmounted for
microscopy. All images were acquired using a confocal microscope LSM880 (Zeiss).
FFPE tissue blocks from murine paws were sectioned at a thickness of 3 mm using a Leica RM1235 microtome. Sections were
mounted on to Superfrost plus (+) slides and left to dry in a slide rack at room temperature for 30 minutes. Slides were heated
(60C) for a minimum of 30 minutes prior to staining. Tissue sections were stained with haematoxylin and eosin (H&E), mounted
with DePex and left to dry overnight. Slides were imaged using an Olympus BX61 microscope for initial grading. 0 = normal; 1 = min-
imal infiltration of inflammatory cells in synovium and periarticular tissue of affected joints; 2 =mild infiltration. 3 =moderate infiltration
with moderate oedema. If referring to paws, restricted to affected joints; 4 = Marked infiltration affecting most area with marked
oedema.
Chemokinesis Assays and Tissue Organ Culture
For the analysis of egressed MCs, equal size tissue sections from juxtaposing areas of tonsil or synovium biopsies were seeded in
48-well-plates in RPMI 1640 supplemented with 10% FBS and treated as indicated in figure. After 4 hours of tissue culture, the su-
pernatants containing egressed cells were collected, followed by staining MCs for CD4, CD8, CD19 or CD14 and counting by FACS
the percentage of events for each cell type. Data were then expressed as percentage fold change as compared to the respective
controls.
Metabolic Profiling
Real-time measurements of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were performed with a Sea-
horse XF96 Extracellular Flux Analyser (Agilent). Briefly, CD4+ T cells were grown in RPMImedium supplemented with 10%FBS. One
hour before the experiment, 3 x 105 CD4+ T cells were seeded in a 96-well microplate in XF Assay medium (Dulbecco’s Modified
Eagle’s Medium, DMEM) in the presence of 10 mM glucose. Sodium lactate or PBS were injected during measurement. Fatty
acid oxidation was analyzed by measuring OCR in the presence of palmitate. Briefly, 2.5 x 105 CD4+ T cells were seeded in a 96-
well microplate in XF Assay Modified DMEM containing 2.5mM glucose. Fifteen minutes before the assay, control cells were treated
with 40mM etomoxir to block CPT-1a. Just before starting the measurements, cells were treated with 167mM BSA-palmitate or BSA
alone (Sigma-Aldrich). During the assay 1mM oligomycin and 1mM FCCP were injected. All data were analysed using XF software.
Intracellular metabolites content was determined by using dedicated quantification kits [NAD+/NADH Quantification Colorimetric
Kit, Citrate Colorimetric/Fluorimetric Assay Kit (BioVision), Acetyl CoA Fluorimetric Assay Kit (BioVision) and NADP+/NADPH Color-
imetric Assay Kit (Abcam)], according to the manufacturer’s instructions.
Reactive oxygen species (ROS) were measured using the fluorescent probe carboxy-H2DCFDA (ThermoFisher Scientific). FFAs
were measured with Free Fatty Acid Colorimetric/Fluorometric Assay Kit (Abcam).
Metabolomics and Stable Isotope Tracing
Following isolation, CD4+ T cells were initially activated in media with anti-CD3 and anti-CD28 mAbs for 24 hours followed by
further 48 hours culture with lactate alone or in the presence of SLC5A12 Ab in medium containing low glucose (5mM) and 5%
FBS. Spent medium was collected and processed for metabolite extraction as described (Mackay et al., 2015). Briefly, medium
from each condition was diluted 50 fold with cold extraction solvent consisting of 50% methanol, 30% acetonitrile and 20%
water. Polar metabolites were extracted by vortexing the tubes for 10minutes followed by centrifugation at 16,0003 g for 10minutes
at 4C. The supernatants were transferred to glass vials and analysed by LC-MS as described (Mackay et al., 2015). Glucose and
glutamine concentrations in the spent medium were quantified using external calibration curves generated by spiking in differente6 Cell Metabolism 30, 1055–1074.e1–e8, December 3, 2019
concentrations of 13C-glucose and 13C-glutamine in the medium and extraction into extraction solvent. Peak areas from the samples
were extrapolated to the standard curve peak areas and absolute concentrations of glucose and glutamine were obtained. Uptake
rates of metabolites (glucose and glutamine) were calculated as difference in concentrations normalized to the area under the growth
curve of cells.
For lactate tracing into polar metabolites, CD4+ T cells were activated for 24 hours in low glucose medium in a 6-well cell culture
plate. The medium was then replaced with fresh medium containing 10mM [U13C]-lactate (Sigma-Aldrich) with or without SLC5A12
Ab and cells were cultured for additional 48 hours. Medium was removed by centrifugation and metabolites were extracted from the
cell pellets with cold extraction solvent (50%methanol, 30%acetonitrile and 20%water). The LC-MS parameters for data acquisition
were kept the same as described (Mackay et al., 2015).
For lactate tracing into palmitate, CD4+ T cells were activated for 24 hours in low glucose medium (5mM) in a 6-well cell culture
plate. The medium was then replaced with fresh medium containing 10mM [U13C]-lactate (Sigma-Aldrich) with or without
SLC5A12 Ab for 0, 24, 48, 72 and 96 hours. At the end of each time point, medium was aspirated and cell pellets were treated
with 750ml of 1:1 cold PBS: methanol and total lipid fraction was extracted in 500ml of chloroform. This extract was dried under inert
nitrogen, reconstituted in 90 ml chloroform and total fatty acids were derivatized using the transesterification reagent MethPrep II
(Thermofisher Scientific, UK) before analysis by GC-MS as described (Tumanov et al., 2015).
For cytokine detection, in the final 4 hours of culture, cells were treated with 50ng/ml PMA and 500ng/ml ionomycin and 1:1.000
brefeldin A (Sigma-Aldrich), followed by surface staining of CD4 (RPA-T4, Biolegend).
To assess the impact of SLC5A12 blockade on cytokine production and CD4+ T cell subsets, we stained activated tonsil MCs,
treated with or without SLC5A12 Ab (48 hours), with BV711–labelled anti–CD4 (clone RPA-T4, 1:100), BV421–labelled anti–PD1
(clone EH12.2H7, 1:100) and PerCP/Cyanine5.5 anti-human CXCR5 (clone J252D4, 5:100). Thereafter, we washed, fixed, and per-
meabilized cells (fixation-permeabilization buffer; eBioscience) and stained with BV450-labelled anti-IL17A (clone BL168, 5:100),
AF488-labelled anti-FOXP3 (clone 206D, 2.5:100), PE-labelled anti-IL10 (clone JES3-19F1, 5:100), FITC-labelled IFNgg (clone
4S.B3, 3:100). Intracellular staining was assessed by flow cytometry using a LSR Fortessa II (BD Biosciences) and FlowJo version
7.6.5 software. All monoclonal antibodies were from Biolegend.
Chemokinesis assays were performed in 5mm trans-well inlays (Corning). One hour before the assay, CD4+ T cells purified from
human PBMCs were incubated with sodium lactate (10mM) and pre-treated (1 hour hour) with SLC5A12 polyclonal Ab (2.5 ug/ml,
Atlas antibodies) or monoclonal mAbs (dilution 1: 50; SLC5A12 mAb clones: 3C7, 4G2, 6E1, 7C1, 9G4, 9G7 and 10E11) purified
from sera of rat immunized with SLC5A12 recombinant peptide or left untreated. In some experiments sodium lactate treated
cells were pre-treated (2 hours) with metabolic drugs: C75 (10uM), TOFA (20uM), DHEA (20uM), DASA (20uM), AICAR (1mM) or
left untreated. For experiments with CD4+ T cells from spleen and lymph nodes of Slc5a12 WT or KO female mice, cells were
incubated with sodium lactate (10mM) or left untreated. In all the assays 3 x 105 lymphocytes suspended in migration medium
(RPMI 2% FCS) were seeded in the upper trans-well chamber; CXCL10 (300 ng/ml) or CCL20 (500 ng/ml) chemokines were added
to the lower chamber. Migrated T cells were counted in cell counting chambers 4 hours after seeding, and then the percentage of
migrated cells was calculated.
Molecular Signaling and Western Blot Analyses
For western blot analyses, proteins were extracted by lysing anti-CD3/CD28 mAbs activated CD4+ T cells (2-4 x 106 per condition) in
RIPA lysis buffer (65mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS and
protease inhibitor cocktail tablets (#04693132001, Roche). Equivalent amounts of protein (30mg), as determined by standard
Bradford assay (Bio-Rad), were loaded, separated by SDS-PAGE and transferred to polyvinyildene difluoride membranes using a
transfer apparatus according to the manufacturer’s protocols (Bio-Rad). After incubation with 5% non-fat milk in TBST (10mM
Tris pH 8.0, 150mM NaCl, 0.5% Tween 20) for 60 minutes, membranes were washed twice with TBST and incubated overnight at
4C with a 1:1000 dilution of primary antibodies against pSTAT3, STAT3, pSTAT1, STAT1, PKM1/2, pACC, ACC, pAMPK, AMPK,
HK1, HK2, enolase1a, GCK, Aldolase, Acetyl lysine, HistoneH3, VDAC, b-Actin (Cell Signalling Technology), PFK (Novus Biologicals),
SLC5A12 (Abcam) Membranes were then incubated for 1 hour hour at room temperature with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit antibodies (1:2000). Blots were washed twice with TBST and developed with the ECL system (Amersham
Biosciences) according to the manufacturer’s protocols. Density of bands was calculated with ImageJ software.
Nuclear, mitochondrial and cytosolic fractions were extracted by using Nuclear Extraction Kit (Abcam) and Mitochondria Isolation
Kit for Cultured Cells (Thermo Scientific) according to the manufacturer’s instructions.
RNA Isolation, Reverse Transcription, and qRT-PCR
Total RNA was isolated from 1 x 106 CD4+ T cells or 10mg RA synovial tissue using RNeasy Mini kit (Qiagen) according to the man-
ufacturer’s instructions and assessed for quality and quantity using absorption ratios of 260/280 nm and 260/230 nm. Cells were
lysed in RLT lysis buffer and nucleic acids were precipitated with 70% ethanol and RNA bound to spin columns. Following several
washing steps, RNA was eluted in dH2O. The isolated RNA was reverse transcribed to complementary DNA (cDNA) using commer-
cially available kits according to the manufacturer’s instructions (Applied Biosystems). Briefly, 1 mg of total RNA was mixed with
buffer, deoxy-nucleotides (dNTPs) and reverse transcriptase and incubated for 2 hours at 30C, followed by a 5 minutes heat inac-
tivation step at 85C. cDNA was diluted to 10 ng/ml and stored -80C for subsequent use.Cell Metabolism 30, 1055–1074.e1–e8, December 3, 2019 e7
Quantitative gene expression analysis was performed using SYBR Green Supermix (Biorad) in CFX connect light cycler (Biorad),
according to themanufacturer’s instructions. Gene relative expression was calculated using theDDctmethod (Livak and Schmittgen,
2001) and normalized to a reference control (GAPDH or ß-Actin). Primers for qRT-PCR were designed with the assistance of online
tools (Primer 3Plus) using at least one exon junction binding-site per primer pair where possible. A complete list of primers is available
in Key Resources Table. Size and specificity of PCR products were confirmed by gel electrophoresis.
RNA Sequencing Analysis
Detailed methodology and analysis of whole RNA-Seq dataset are described in Lewis et al., 2019). RNA was extracted from synovial
tissue homogenised at 4C in Trizol reagent. Library preparation was performed using TruSeq RNA Sample Preparation Kit v2 (Illu-
mina). Multiplexed libraries were sequenced on Illumina HiSeq2500 to generate 50 million paired-end 75 base pair reads per sample.
Synovium transcript abundances were quantified from RNA-Seq FASTQ files over GENCODE v24/GRCh38 transcripts using Kallisto
v0.43.0. Estimated read counts generated using tximport 1.6.0 were normalised using DESeq2 1.18.1, accounting for average tran-
script length correction, incorporating batch, sex and pathotype as model covariates. Transcript abundances were normalised and
converted to regularised log expression (RLE). Differential gene expression analysis was performed using DESeq2 with likelihood
ratio test between pathotype or ELS group. Q-values were calculated using Benjamini-Hochberg false discovery rate (FDR), with
a cut-off of Q% 0.05 to define differentially expressed genes.
Gene sets highly specific to immune cell tissue types were derived based on CAGE sequencing data from the FANTOM5 project
(Dimont et al., 2014). Module scores specific for T cell subsets were analysed for correlation with metabolic gene expression in sy-
novial tissue.
Hierarchical clustering within seven groups of metabolic genes differentially expressed between synovial biopsies classified as
positive or negative for ELS by histological analysis (FDR% 0.05) was performed using Euclidean distancemetric andWard’s linkage
method and plotted using ComplexHeatmap 1.17.1.
Metabolic genes were selected via the use of the KEGG pathway database.
ELISA
Secreted IL17A and IFNg were measured in cell culture supernatants from 2-4 x 106 CD4+ T cells/well with a human IL17A (homo-
dimer) and IFNg ELISA Ready-SET-Go Assay (fisherscientific) respectively, according to the manufacturer’s instructions.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments can be found in the figure legends. All data are expressed as ± SD or ± SEM as indicated in figure
legends. Statistical tests were selected based on appropriate assumptions with respect to data distribution and variance character-
istics. Statistical significance was determined using unpaired Student’s t test or ANOVA (one- or two-way). ll statistical analysis were
carried out in GraphPad Prism7. Significant differences are indicated as follows: *p% 0.05, **p% 0.01, ***p% 0.001.
DATA AND CODE AVAILABILITY
RNA-seq data are deposited at ArrayExpress and are accessible via accession E-MTAB-6141 (https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-6141).e8 Cell Metabolism 30, 1055–1074.e1–e8, December 3, 2019
